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Cancer, currently the second leading cause of death in the United States, is expected 
to become the first killer in the near future by surpassing heart diseases. Molecular imaging 
has become a key tool in the biomedical research and clinical diagnosis. By employing 
specific imaging probes, molecular imaging traces various biological processes at the 
molecular level in living tissues with high resolution and specificity. In this dissertation, 
the early assessment of clinical radiotherapy effects has been carried by positron emission 
tomography (PET) imaging with F-18 labeled 2-(5-fluoropentyl)-2-methyl malonic acid 
(F-18 ML-10). However, most of the researches on application of F-18 ML-10 are 
preclinical studies. 
Currently, the clinical assessment of radiotherapy effects is based on the measurement 
of tumor size by magnetic resonance imaging (MRI) 2-4 months post radiotherapy. 
However, several months’ late assessment caused many patients who is bearing malignant 
tumor to lose the chance of surrogate therapy. This has caused an impediment for the 
management of therapy plan. Therefore, there is a great demand for early assessment of 
radiotherapy of cancer in the clinic. As apoptosis of tumor cells is one of the early events 
that occurred after radiotherapy, therefore monitoring of apoptotic cells by F-18 ML-10 
PET imaging can be used for the early assessment. However, there are many challenges 
for its clinical use. 
As is produced through F-18 fluoride labelling via nucleophilic substitution reaction, 
Kryptofix 2.2.2 (K2.2.2) is one of the most widely used phase-transfer reagents for F-18 
nucleophilic substitution reaction. Due to the toxicity of K2.2.2, its residue in F-18 
 xx 
radiopharmaceuticals should not exceed 50 g/mL, as required by the United States 
Pharmacopeia 40. However, false-positive or false-negative results of K2.2.2 detection 
affects the safety of F-18 pharmaceuticals. In this dissertation, we have overturned the 
hypothesis that amine compounds caused the false positive results. Moreover, we also 
proposed and tested the effect of reductive stabilizer and pH value on the false negative 
results. 
In the investigation on safety assessment of radiotherapy, a special clinical case for 
therapeutic assessment on lung cancer after CK treatment has been investigated. After CK 
treatment, there was no significant change in the apoptosis of tumor. However, the 
apoptosis in heart tissue and aortic arch increased significantly, indicating injuries in 
adjacent tissue by CK treatment caused by a rapid apoptotic response. The late return visit 
indicated that the cancer recurred, this is coincident with the F-18 ML-10 imaging results. 
This finding was verified by following preclinical studies on rabbits. Thus, this case study 
suggested that this method has the potential for the assessment of subsidiary-injury of lung 
cancer radiotherapy. 
In the investigation on efficacy assessment of radiotherapy, in the clinical applications, 
29 clinical cases of different types of brain tumor have been included, and the PET image 
has been analyzed volume-by-volume in assessment of response of different types of 
tumors to CyberKnife (CK) radiotherapy. There are many challenges for quantitative 
analysis of therapeutic assessment by using apoptosis imaging. As apoptosis is essentially 
a transient process, it is necessary to standardize the imaging method and time point, and 
to make quantitative analysis based on “volume-by-volume” of the image, to distinguish 
between cell apoptosis and spontaneous apoptosis. Furthermore, correlation between the 
 xxi 
result of this early assessment and subsequent anatomic change in tumor determined by 
MRI was also investigated. The results show a high correlation between the F-18 ML-10 
imaging results and the tumor volume changes evaluated by MRI. This research has 
provided a clinical method for the early evaluation of tumor radiotherapy. The applicability 
of this method has been discussed by analyses on different brain tumor types. 
In addition, two other imaging related projects which I have done during my PhD 
period are also included in this dissertation. For the application of spectroscopic molecular 
imaging to real-time surgery guidance, the sensitivity of a novel surface enhanced Raman 
spectroscopy (SERS) hand-held spectroscopic device for intraoperative tumor detection 
has been investigated. The SERS gold nanoparticles have been proved to be ultra-high 
sensitive for in vitro detection with wide dynamic range, thus could distinguish the signal 
of tumor tissue from that of normal tissue. Furthermore, the differentiation of tumor tissue 
from inflammatory tissue has also been investigated by a preclinical quad-modality 





CHAPTER 1. INTRODUCTION 
An estimated 1,688,780 new cases of cancer will be diagnosed in the United States 
and 600,920 people will die from the disease in 2017 [1]. The World Health Organization 
(WHO) has published the “World Cancer Report 2014”, analyzing the overall situation and 
current trends of cancer among more than 180 countries and 28 types of carcinoma around 
the world. According to this report and data from National Cancer Institute (NCI), the 
global number of people living beyond a cancer diagnosis, having reached 14 million in 
2012, is predicted that the global cancer cases will show a rapid growth. It is expected to 
reach 19 million in 2025 [2]. The annually global expenditures for cancer care totaled higher 
than $895 billion. In China, the estimated nationwide 5-year cancer prevalence was 7.49 
million, and the 5-year prevalence proportion was 556/100,000 [3]. 
1.1 Current challenges in cancer therapeutics 
“To cure sometimes, to relieve often, to comfort always” is a well-known quotation 
from Dr. Edward L. Trudeau in nineteenth century. Although have many new technologies 
been developed in the past century, there is still lack of effective therapeutics for many 
diseases especially cancer. The variation in the biologic behavior of tumor is one of the 
major challenges for complete elimination of cancer [4, 5]. To make a progress on cure of 
cancer and personalized healthcare, President Obama launched “Precision Medicine 
Initiative” in January 2015. Personalized healthcare is helpful in medical practice, and 
information in the molecular level will make medicine more precise. 
1.1.1 Challenges in early diagnosis 
 2 
With traditional diagnostic methods, cancer could not be diagnosed in a very early 
stage. Patients in many cases are not diagnosed until the tumor has been growing to later 
stage with significant size or effect to their health. Clinical results show that the 
improvement of the five-year survival rate of cancer patients is mainly due to early 
diagnosis followed by proper therapeutics with currently available treatment technology 
and methods. Therefore, early diagnosis is an important way to improve the treatment 
outcome and reduce medical expense. 
1.1.2 Challenges in early assessment after treatment 
There are more than 20,000 of newly diagnosed brain tumor patients in the United 
States each year, of which 70% were malignant glioblastoma multiforme (GBM) [6-8]. 
However, the average survival period after therapy is only 12 to 15 months. In this situation, 
it is needed to make a breakthrough not only in therapeutic method, but also in assessment 
early after therapeutic. Currently, the most common method to assess therapeutic outcome 
is magnetic resonance imaging (MRI), by comparison the morphological change of tumor. 
However, there are limitations of the application of this method in terms of early evaluation, 
since the changes in tumor size usually takes a certain period before being reflected, and 
therefore cannot accurately reflect the changes in the molecular physiology of tumors at an 
early stage. 
Nowadays, the most common radical cancer treatments are surgery, radiotherapy and 
chemotherapy. Among them, radiotherapy is an important method for intracranial 
treatment that could either be a main regiment, or adjuvant therapy after surgery for 
keeping cancer from recurrence. The evaluation of therapeutic response mainly relies on 
 3 
the change of tumor size assessed by computed tomography (CT) and MRI images. For 
radiotherapy and chemotherapy, however, the anatomical volume change comes later than 
the rapid biological change on cellular level, resulting in a serious lag effect for the 
evaluation [9]. Indeed, the anatomical volume change of intracranial tumor is difficult to be 
visualized by CT or MRI till 4-8 weeks after whole brain radiotherapy [10, 11]. Particularly, 
for patients with malignant brain tumor, such as high-grade gliomas and metastatic tumors, 
etc., the average survival time is short. With the lag effect of conventional assessments, the 
early response after radiotherapy is hard to be assessed which might result in a delay or 
loss of chance for an alternative treatments [12-14]. Moreover, the tumor tissue and radio-
necrotic tissue could not be distinguished by CT and MRI images, which might cause 
ambiguous or even wrong judgment of therapeutic effect. Therefore, a method which could 
offer an early response assessment after radiotherapy for clinical management 
improvement is required. 
Apoptosis is a basic biological process regulating cell death and playing an important 
role in many diseases. Apoptosis imaging has been widely applied to visualize tumor 
hallmark [15-29]. Spontaneous apoptosis in tumors is increased than in normal tissue, and 
apoptosis generally reflects tumor molecular physiological processes, which could be used 
as a useful indicator of tumor progress by comparing the apoptosis imaging before and 
early after treatment. 
1.2 Molecular imaging 
1.2.1 Precision medicine 
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The principle of precision medicine, formerly known as personalized medicine, is 
using of specialized treatment for particular disease from a specific patient, at a particular 
time. However, we still cannot classify those diseases, patients and treatments based on 
current research progress of biology or medicine. Unlike genome-wide associated study 
(GWAS), molecular imaging does not focus on the mechanism of tumorigenesis. To 
achieve precision medicine, molecular imaging provides an approach to visualize 
physiological changes in early stage of cancer from the signal of molecular probes. 
1.2.2 Molecular imaging 
Imaging is a brilliant strategy to get information without knowing the detailed 
activities of biological processes. As shown in Figure 1.1, recent advances of molecular 
imaging provide great opportunities for early diagnosis of cancer [30-32]. In the past decade, 
researches on drug design, discovery, and delivery have enhanced the performance of 
chemotherapy and radiotherapy by improving the selectivity and reducing the toxicity [33, 
34], thus providing effective therapeutic regimen especially for the treatment of widespread 
tumors. Molecular probes are specifically modified molecules those who could visualize 
specific physiological information. Once after being injected in human body, molecular 
probes could recognize then combine with certain biomarker such as receptor, enzyme, 
nucleic acid, etc. By visualizing the signal from molecular probe from high-precision 
imaging, we could obtain molecular information of disease progression. 
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Figure 1.1 – Development of molecular imaging used in oncology. Reprinted from 
Weissleder and Pittet [30] with permission. Copyright © 2008 Nature Publishing 
Group. 
In clinical trials, the regular treatment for localized and locally advanced tumor is still 
dominated by surgical resection combined with chemo or radiology. Especially, compared 
to non-surgical treatment, surgery could greatly improve the survival of patients, by 
accurate tumor staging and complete removal of lesions. According to statistics, surgery 
can prolong survival rate of patients with lung cancer 10 times, thus surgery is still the 
preferred option for cancer treatment. During surgery, however, the surgeon still mainly 
dependent on two tools: the eyes to look suspicious tissue, and the hands to feel abnormal 
tissue; thus inevitably causing problems with incomplete excision, thereby leading to tumor 
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recurrence and metastasis, which is the biggest problem of tumor surgery, because once 
the recurrence and metastasis, then surgery is extremely difficult to occur, which seriously 
affected the survival of patients [35]. According to statistics, the ratio of patients with 
postoperative local recurrence of tumor after surgery reaches 40%. As the molecular 
imaging could accurately distinguish cancerous and normal tissues, detect and locate 
cancerous tissue, especially tumor accurately determine edge positions, which will greatly 
increase the possibility complete resection of the tumor, the surgical accuracy could be 
improved significantly. The second specific aim of this project is focused on an 
investigation on sensitivity of hand-held spectroscopic imaging device for surgery 
guidance. 
With the completion of Human Genome Project and the progress of gene sequencing 
of various animals, it has been found that the genes of mice that commonly used in 
laboratory is highly homologous to human [36]. The development of transgenic technology 
has made it possible to project human diseases to animal models, used to support the 
research of related diseases, the development of new drugs, and the evaluation of drug 
efficacy [37-39]. Due to the differences between individuals, in vivo imaging is critical to the 
diagnosis and treatment of cancer. Since the 1980s, the Medical Imaging technology has 
been developed from the traditional single structural imaging towards the stage of multi-
modal functional and Molecular Imaging. The development of genomics and molecular 
biology has improved our understanding of diseases into the cellular and molecular level. 
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Figure 1.2 – Active targeting and hallmarks of cancer. Reprinted from Hanahan et al 
[40] with permission. Copyright © 2011 Elsevier Inc. 
Dr. Ralph Weissleder and colleagues first proposed the concept of Molecular Imaging 
(MI) in 1999 [41], which means applying the imaging methods to perform qualitative and 
quantitative research on biological process in vivo at the cellular and molecular level [42, 
43]. This method uses specific biomarker in human body as the target of molecular probes, 
and noninvasively images the internal physiological or pathological processes at the 
molecular level, based on existing medical imaging technologies, as depicted in Figure 1.2 
[40]. The molecular imaging integrates physiological information, which is then detected by 
sophisticated imaging technique and processed through a series of image post-processing 
techniques, to represent the real-time biological processes in vivo at the cellular and 
molecular level. 
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1.2.3 Principles of molecular imaging for early diagnosis 
Since it was proposed in 1990s, molecular imaging has become a key tool in the 
biomedical research and clinical imaging [44, 45]. Molecular imaging traces the biological 
processes at the molecular level in living tissues with high resolution and specificity, 
sensing diseases at their very early stage. Various molecular imaging methods based on 
different mechanisms, such as the radiolabeling and optical labeling, have gained 
significant progresses over past decades [46-64]. The most common imaging modalities are 
CT, positron emission tomography (PET), single photon emission computed tomography 
(SPECT), MRI, and ultrasound, etc. 
However, a living body is an extremely complex system, imaging such system using 
a single biomarker is generally not enough to understand its physiology. Even a simple 
biological process gets involved in many biochemical reactions, and a single biomarker 
might only partially represent the process. Moreover, different biological processes may 
have overlap in molecular reactions. For instance, both cancer and inflammation can cause 
abnormal metabolic activities, so that tracing the glucose metabolism alone cannot separate 
these two distinct diseases. Thus, using multiple biomarkers that could trace different 
biological processes in the living animal is of great desire for biomedical research. On the 
other hand, the use of different biomarkers vary in depth, location, chemical property, and 
concentration, etc., which require multimodal imaging methods [65]. Therefore, multimodal 
and multi-probes molecular imaging gain increasing interest and will have great impact on 
the biomedical imaging [66-78]. 
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Multi-modality imaging, which is capable of providing non-invasive and real-time in 
vivo observations of biomedical processes, has been developed for preclinical researches, 
such as new pharmacological studies, drug distribution, disease diagnosis, especially in 
cancer research [44, 45]. In general, imaging modalities could be divided into anatomical and 
functional imaging. Anatomical imaging modalities, such as ultrasound imaging, computed 
tomography (CT) and magnetic resonance imaging (MRI) can provide anatomical 
information whereas the functional imaging modalities [e.g. positron emission tomography 
(PET), single photon emission computed tomography (SPECT) and fluorescence imaging 
(FMI)] excel at detecting or measuring changes in metabolism, blood flow, regional 
chemical composition, and absorption that very often use tracers or probes to reflect spatial 
distribution of them in the body. However, each single molecular imaging method cannot 
answer all biological questions and is inadequate to meet ever increasing demands of 
resolution, sensitivity and specificity in today’s scientific research. An ideal imaging 
method should be able to furnish anatomical, physiological, and molecular information 
with high sensitivity, specificity and good resolution. Because no single imaging modality 
can provide information on all these aspects, it is very desirable that a system combines 
these imaging modalities to harness the strengths of different imaging methods. Following 
the development of the first dual-modality imaging system[53, 54], which combined SPECT 
and CT, the concept of multi-modality imaging technology has been widely recognized 
and accepted in both preclinical and clinical studies. Therefore, most of the multi-modality 
imaging combinations have been devoted toward integrating one technique from each 




Figure 1.3 – Integration of the Quad-modality imaging system. (a) Draw of quad-
modality imaging system, which consisted of the PET, CT, SPECT and FI imaging 
modules. (b) Photograph of the quad-modality imaging system, which can be setup 
on an optical table. Reprinted from Lu et al [78] with permission. Copyright © 2014 
Society of Nuclear Medicine and Molecular Imaging, Inc. 
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Another important aspect of the multi-modality imaging comes from a surge in 
research and technology developments of novel molecular probes [65]. For molecular 
imaging research, the rise in multi-modality probes has sparked great desires for new 
technologies in research on multi-modality instrumentation development to measure 
multiple molecular targets simultaneously or in immediate sequence during the same 
session. In this condition, several multi-modality imaging systems have been developed 
for multi-probe imaging that might offer many advantages for preclinical studies [55, 56, 58, 
60, 61, 63].  
In these multi-modality imaging systems, SPECT, PET, FI modalities use the idea of 
tracers to image physiologic processes in vivo and the CT modality provide anatomic 
information for co-registration. While PET and SPECT generally detects high energy 
gamma rays emitted from radioactive molecular tracers, bioluminescence or fluorescence 
tracers are traditionally imaged with FMT that detects low energy light (visible or near-
infrared light). SPECT permits to use many tracers and biomarkers, which can image a lot 
of physiologic processes. In contrast with SPECT, PET has the advantages of high 
sensitivity and temporal resolution, but permits small number of isotope tracers and 
generally gives metabolic information. FI has high sensitivity and specificity, but low 
spatial resolution and imaging quality that caused by tissue scattering has limited its 
applications. These functional imaging modalities have their respective pros and cons but 
can complement and consult each other. For instance, although PET has high sensitivity in 
metabolic information but sometimes difficult to differentiate the inflammatory response 
versus cancer’s process, with optical tracers and SPECT tracers, which although have low 
spatial contrast and low sensitivity respectively, however with the fusion imaging that can 
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give the complementary information, significantly improve the specificity. It can be 
harness to more comprehensive information that performing several different molecular 
probes to detect the same site in immediate sequence during the same session, several 
critical but complementary biomedical information can give more accurate understanding 
of the process. Thus, to combine two or three of these functional imaging modalities 
providing complementary information is a worthwhile goal. 
Several articles [50, 51, 57, 67, 75, 76] have discussed the feasibility and potential 
opportunities of combining the PET-SPECT and radiology-optical imaging modalities, and 
recommended to use these kind of strategies in biomedical research. Yet so far none of 
such this imaging system that combines all the three functional imaging modality of PET, 
SPECT and FI has been developed. Considering this, in this paper we proposed a strategy 
about tetra-modality molecular imaging that combines PET, SPECT, FI, and X-ray CT 
modalities for molecular imaging research. Specifically, PET, SPECT and FI modalities 
provide functional information in different aspects, and CT modality plays a vital role of 
providing anatomical data as structural reference. 
The quad-modality imaging system used modular design, i.e., PET, CT, SPECT and 
fluorescence molecular tomography (FMT) modalities were designed and manufactured 
separately. A line-type X-ray detector with a helical scan mode was used in the CT module 
and a design of a rotary transmission module. On the same rotating plate with CT, SPECT 
system was installed (as seen in Figure 1.3), which has two gamma cameras anti-parallelly 
opposed to increase the axial field of view (FOV) of SPECT that can cover the whole-body 
area of most mice. The gamma camera has a 22  22 cerium doped lutetium-yttrium 
oxyorthosilicate (LYSO) scintillator array coupled to a Hamamatsu H8500 position 
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sensitive multi-anode photomultiplier tube (PS-PMT) by optical silicone oil. It took 10 - 
20 minutes to finish one SPECT whole-body imaging of a typical nude mouse. The next 
individual module is PET, which is a fixed ring that contains 54 silicon photomultiplier 
(SiPM) based detectors. It takes 30 - 40 minutes to scan a mouse (three or four bed 
positions). On the end side of the system, a non-contact, full-angle and vertically rotating 
FMI imaging module was installed. The FMI can carry out not only traditional fluorescence 
2D imaging with both epi-illumination and trans-illumination, but also tomographic 3D 
imaging. It took less than 10 seconds and 10 minutes to complete traditional 2D imaging 
and tomographic 3D imaging, respectively. In addition, a transparent animal bed was 
mounted on a high-precision motor-controlled one-dimensional translation stage, which 
carried the animal from one modality to another automatically. The entire imaging system 
can be installed on a 900 mm  1500 mm optical table (Figure 1.3b).  
The PET, SPECT and CT modules were set up on one side of the motor-controlled 
animal bed, and the FMI module was placed on the other end because that FMI module 
requires strictly light shielding. The animal bed can be shifted between PET/SPECT/CT 
imaging and FMI imaging for multi-modality imaging fusion and so that each imaging 
module can acquire information data precisely with the co-registered animal position. In 
this way, this design not only achieved a compact multimodality system but also facilitated 
the shading of radiation and undesired light. Geometric calibration and image co-
registration was processed using fiducial markers on the animal holder. The coordinates of 
the fiducial markers in images acquired were used for the geometrical transformations 
leading to the fusion of multi-modality images. 
1.2.4 Imaging-guided therapy 
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In the 2009 World Molecular Imaging Congress, the concept of molecular imaging 
guided cancer surgery was proposed by Dr. Roger Y. Tsien, and a relevant preclinical 
research was published in 2010, showing a guided resection of tumor tissue in mice by 
fluorescence microscopy [79]. The first clinical trial of fluorescence imaging guided ovarian 
cancer surgery was conducted by Leiden University Medical Center in 2011 [80]. Since then, 
the molecular imaging-guided cancer surgery has become a globally hot area in precision 
medicine especially cancer research [81-83]. 
 
Figure 1.4 – A hand-held spectroscopic device for intraoperative tumor detection. 
Reprinted from Mohs et al [82] with permission. Copyright © 2010 American Chemical 
Society. 
With imaging guided therapy, surgeons could accurately determine and locate the 
tumor tissue, especially margin area, thus could significantly increase the possibility of 
completely removing the entire tumor. As shown in Figure 1.4, a hand-held spectroscopic 
device for intraoperative tumor detection has been developed by our group [82]. The 
sensitivity of this real-time imaging is the most important factor for guidance during 
surgery, since the signal of tumor margin or satellite tumor tissue could be much lower. 
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Traditional molecular probes for imaging-guided surgery is indocyanine green (ICG), a 
fluorescent dye being injected intravenously prior to surgery. 
1.3 Molecular probes 
In molecular biology, molecular probe refers to the labeled deoxyribonucleic acid 
(DNA) or ribonucleic acid (RNA) used to detect the complementary nucleic acid sequence; 
while in terms of molecular imaging, the molecular probe refers to the molecules, such as 
ligands or antibodies, that can specifically bind with the target tissues, to form a compound 
with molecules that can produce imaging signals (such as isotopes, fluorescein, etc.) in a 
particular way (as shown in Figure 1.5).  
 
Figure 1.5 – Various types of molecular probes. Reprinted from Weissleder and Pittet 
[30] with permission. Copyright © 2008 Nature Publishing Group. 
With the molecular probe, the molecular and genetic information could be indirectly 
revealed through the signal change detected by the high-resolution imaging system, based 
on the principles of targeted binding or enzyme activating [84-107]. The molecular probe 
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should be able to bind with a specific molecular target in vivo, and provide signal to be 
detected. Therefore the following three requirements should be met when designing a 
molecular probe: (1) high specificity and affinity with the target molecule; (2) ability to 
pass through physiological barriers in vivo and to reach the target cells; (3) high 
biocompatibility and stability, while participating the relative physiological processes in 
vivo [71, 73, 108-132]. 
1.3.1 F-18 ML-10 apoptotic PET imaging 
Currently, three types of widely used apoptosis probes are proteins, non-specific small 
molecules and caspase activation. However, the limitations such as poor specificity, slow 
blood clearance and immunogenicity etc. impede these probes’ clinical applications. An 
ideal apoptosis probe for clinical practice should be specific for apoptotic cells, with rapid 
clearance, nontoxic, and high stable [28, 133, 134]. Tc-99m labeled annexin V and F-18 labeled 
2-(5-fluoropentyl)-2-methyl malonic acid (F-18 ML-10) are the only two clinically 
available radiotracers for apoptotic imaging, and the latter is the only probe for PET 
imaging. ML-10 is derived from the Aposense family apoptotic biomarker. F-18 ML-10 
(as shown in Figure 1.6), a low-molecular mass (molecular weight = 206) PET apoptotic 
tracer derived from Aposense family, is the first clinically available apoptosis probe for in 
vivo imaging. 
 
Figure 1.6 – F-18-labeled 2-(5-fluoropentyl)-2-methyl malonic acid (F-18 ML-10). 
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Figure 1.7 – Mechanism for ML-10 uptake by apoptotic cells. Reprinted from Cohen 
et al [135] with permission. 
Being investigated in multi-center preclinical and clinical trials, F-18 ML-10 shows 
high stability, safety, specificity, and rapid biodistribution [22, 23]. As a probe to visualize 
cell apoptosis in vivo, F-18 ML-10 selectively accumulates in apoptotic cells by 
recognizing alterations on the surface of apoptotic cells [19, 20], thus the apoptotic cells could 
be distinguished from normal cells. Additionally, F-18 ML-10 could be transported 
through cytoplasmic membrane in apoptotic cells, whereas there is no F-18 ML-10 
membrane transportation in necrotic cells. Aposense compounds are rationally designed to 
selectively bind and accumulate in cells manifesting apoptosis-specific alterations, 
collectively designated the apoptotic membrane imprint with following steps [135]: 
1. Acidification of the external membrane leaflet due to exposure of 
phosphatidylserine from apoptotic cells; 
2. Permanent membrane depolarization; 
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3. Irreversible loss of intracellular pH control; 
4. Activation of the phospholipid scrambling mechanism while membrane integrity is 
still preserved. 
The concurrence of these apoptotic membrane imprint features marks the commitment 
point of a cell to the apoptotic death process, thus distinguishing such a cell from its viable 
or necrotic counterparts F-18 ML-10 manifested selective binding to apoptotic cells, high 
stability, and a favorable biodistribution profile on systemic administration in vivo. 
1.3.2 Safety by quality control of F-18 radiopharmaceuticals 
Safety is one of the most important aspects for pharmaceuticals to investigate by 
preclinical and clinical studies before applying to patients. Quality control is an important 
method to assure the safety of pharmaceuticals. F-18 radiopharmaceuticals are commonly 
produced by F-18 fluoride labelling via nucleophilic substitution reaction. As shown in 
Figure 1.8, 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo (8.8.8) hexacosane (Kryptofix 
2.2.2, K2.2.2) is one of the most widely used phase-transfer reagents for F-18 nucleophilic 
substitution reaction, as well as the main source of chemical impurities in F-18 
radiopharmaceuticals. However, the toxicity of K2.2.2 has been revealed by investigation 
on rodents [136, 137]. As an important quality control requirement, its residue in F-18 
fluorodeoxyglucose (F-18 FDG) injection should not exceed 50 g/mL, required by the 
United States Pharmacopeia 40 (USP 40) [138] and Chinese Pharmacopoeia (ChP) 2015 [139]. 
The European Pharmacopoeia (EP) 9.0 [140] proposed a maximum permissible level of 2.2 
mg/V as patient dose, which is higher than the threshold set by USP 40 and ChP 2015. 
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Figure 1.8 – 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo (8.8.8) hexacosane (Kryptofix 
2.2.2). 
Currently, a number of methods have been developed to measure the residue of K2.2.2 
in F-18 radiopharmaceuticals, such as thin layer chromatography (TLC) [141-144], gas 
chromatography (GC) [145], high performance liquid chromatography (HPLC) [146, 147], 
liquid chromatography-tandem mass spectrometry (LC/MS/MS) [148], spectroscopy  etc. 
Among them, the iodoplatinate staining spot test on TLC, described by Mock BH and 
Colleagues [143], has been adopted by Chinese Pharmacopoeia 2015 and European 
Pharmacopoeia for the detection of K2.2.2 in F-18 FDG [139, 140]. This is a great step in 
quality control of F-18 radiopharmaceuticals in China. In previous version of Chinese 
Pharmacopoeia, the proposed method was spectrophotometry. As the minimum volume for 
spectrophotometry was 0.3 mL, it was impossible to do the quality control prior to injection. 
Therefore, the retrospective quality control was required. In current version of Chinese 
Pharmacopoeia, the spot test method has been adopted. With the spot test, only 3 L is 
required for the detection. Therefore, the quality control can be conducted prior to injection, 
which could better assure the safety of radiopharmaceuticals. However, as other tertiary 
amine can also react with the iodoplatinate reagents on the silica gel plate [149], such 
interference could result in a false-positive or false-negative reaction [143, 150]. Therefore, 
the amine’s interference to the result has been considered as a limitation of the application 
of the spot test [143, 151]. 
 20 
1.4 Research objectives 
The goal of this thesis is to investigate the assessment of radiotherapy of cancer by F-
18 ML-10 apoptosis imaging. In this dissertation, I hypothesize a method to early assess 
the safety and efficacy of radiotherapy by apoptosis imaging. In the safety assessment, this 
method monitors subsidiary injury from exposure of irradiation by measurement of 
apoptosis change in adjacent tissue outside tumor area. In the efficacy assessment, this 
method monitors early apoptosis change in tumor area, to predict the tumor shrinkage in 
several months. 
The apoptotic cells and normal cells have been classified by F-18 ML-10 clinical 
imaging, to validate the following unsolved scientific problems: 
1. The interference on K2.2.2 detection in F-18 pharmaceuticals synthesis via spot 
tests remains unclear. 
2. With the lag effect of conventional assessments, the early response after 
radiotherapy is hard to be assessed which might result in a delay or loss of chance for 
alternative treatments. 
3. It is a challenge to quantitative assessment of apoptosis response of intracranial 
tumor early after radiotherapy. 
4. Although F-18 ML-10 apoptosis imaging has been applied in some case reports [9, 
19, 20, 22], the application of the assessment for lung cancer early after radiotherapy has not 
been reported. 
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In other related works included in this dissertation, the tumor tissue and inflammatory 
tissue have been distinguished by preclinical quad-modality imaging with novel probes, 
and the sensitivity of real-time intraoperative imaging for surgery guidance to distinguish 
the tumor tissue and normal tissue has been investigated. 
Therefore, I started to investigate the safety and quality control of F-18 ML-10 in the 
synthesis process, to reveal the mechanism of interference in K2.2.2 detection in F-18 
radiopharmaceuticals synthesis via spot tests.
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CHAPTER 2. QUALITY CONTROL OF F-18 ML-10 
 As an F-18 radiopharmaceutical, F-18 ML-10 is commonly produced by F-18 
fluoride labelling via nucleophilic substitution reaction. K2.2.2 is one of the most widely 
used phase-transfer reagents for F-18 nucleophilic substitution reaction, as well as the main 
source of chemical impurities in F-18 radiopharmaceuticals. The removal and detection of 
K2.2.2 residue in F-18 ML-10 is important in synthesis and quality control process. 
However, false-positive or false-negative results curb the accuracy of K2.2.2 detection. 
Although amines have long been considered as the main cause of false-positive or false-
negative results of K2.2.2 detection by spot tests, this chapter suggests instead that it is the 
pH of the sample solution that produces the false-negative results. It is also shown that such 
interference cannot be attributed to the presence of amines. Commonly used reagents’ 
interference in the detection of K2.2.2 by spot tests was also determined in this chapter. 
Through testing reagents and stabilizers that are commonly utilized in the process of 
synthesis of F-18 radiopharmaceuticals, ascorbic acid was found to interfere in the spot 
test, resulting in a false-negative result. 
2.1 Introduction 
F-18 radiopharmaceuticals are commonly produced by F-18 fluoride labelling via 
nucleophilic substitution reaction. K2.2.2 is one of the most widely used phase-transfer 
reagents for F-18 nucleophilic substitution reaction, as well as the main source of chemical 
impurities in F-18 radiopharmaceuticals.  
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Figure 2.1 – K2.2.2 as the catalyst in F-18 pharmaceuticals synthesis. Reprinted from 
Hamacher et al[152] with permission. 
As shown in Figure 2.1, in the process of synthesis of F-18 radiopharmaceuticals, the 
1,3,4,6-tetra-O-acetyl-2-O-triflate-beta-D-mannopyranose were utilized as a precursor, 
and the K2.2.2 was also added as a phase-transfer catalyst[152]. Due to the toxicity of K2.2.2 
[136, 137], its residue in F-18 fluorodeoxyglucose (F-18 FDG) injection should not exceed 50 
g/mL, required by the United States Pharmacopeia 40 (USP 40) [138] and Chinese 
Pharmacopoeia (ChP) 2015 [139]. The European Pharmacopoeia (EP) 9.0 [140] proposed a 
maximum permissible level of 2.2 mg/V as patient dose, which is higher than the threshold 
set by USP 40 and ChP 2015. 
Currently, a number of methods have been developed to measure the residue of K2.2.2 
in F-18 radiopharmaceuticals, such as thin layer chromatography (TLC) [141-144], gas 
chromatography (GC) [145], high performance liquid chromatography (HPLC) [146, 147], 
liquid chromatography-tandem mass spectrometry (LC/MS/MS) [148], spectroscopy  etc. 
Among them, the iodoplatinate staining spot test on TLC, described by Mock BH and 
Colleagues [143], has been adopted by Chinese Pharmacopoeia and European 
Pharmacopoeia for the detection of K2.2.2 in F-18 FDG [139, 140]. However, as other tertiary 
amine can also react with the iodoplatinate reagents on the silica gel plate [149], such 
interference could result in a false-positive or false-negative reaction [143, 150]. Therefore, 
the amine’s interference to the result has been considered as a limitation of the application 
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of the spot test [143, 151]. In our experience of quality assurance of F-18 pharmaceuticals, 
however, the presence of amine occasionally leads to false-negative results, but not leading 
to false-positive results, by spot test. Here, we investigated the amine’s contribution to the 
iodoplatinate staining spot test for K2.2.2 detection by a semi-quantitative method. 
Furthermore, as the stabilizer has also been reported leading to a false-negative result [150], 
we also investigated the interference from stabilizers and other reagents commonly used in 
the synthesis of F-18 FDG. 
2.2 Results and discussion 
2.2.1 Detection limit of K2.2.2 by iodoplatinate staining spot test 
 
Figure 2.2 – Visualization of K2.2.2 at concentrations of 1 g/mL (a), 2 g/mL (b), 5 
g/mL (c), 10 g/mL (d), and 50 g/mL (e). The inner dark bluish circles represent 
the visualization of K2.2.2. 
Two concentric circles can be visualized on the silica gel plate, after applying 3 L 
droplet of K2.2.2 at certain concentration. As depicted in Figure 2.2, the outer circle, with 
brown color, represents the solvent; whereas the darker one, innermost bluish circle, is 
from K2.2.2. The spot with highest concentration of K2.2.2 is shown in Figure 2.2e, and 
the dark bluish circle is clearly visible by naked eye (Figure 2.2e). With further dilution, 
from 50 to 1 g/mL (Figure 2.2a – e), the intensity of dark bluish circle decreased 
accordingly. Finally, the signal of dark bluish circle cannot be detected by digital camera 
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at 2 g/mL (Figure 2.2b). Therefore, the detection limit of K2.2.2 by this method is 5 
g/mL (Figure 2.2c). 
2.2.2 Amine’s interference on spot test for K2.2.2 detection 
Two concentric circles can be visualized on the silica gel plate, after applying 3 L 
droplet of 50 g/mL K2.2.2 on it. As depicted in Figure 2.3a, the outer circle, with brown 
color, represents the solvent, while the darker one, innermost bluish circle, is the signal 
from K2.2.2. 
With this spot test, the interference from each amine-containing sample could be 
analyzed by comparing the color and intensity of the dark bluish circular signal from spot 
B and C. As the spot C is from K2.2.2 standard solution, the color and intensity of this dark 
bluish circular signal in spot C could be considered as the reference of K2.2.2 without any 
interference. By visually comparing the color and intensity of K2.2.2’s signal in spot B 
with spot C, the amine’s interference to the spot test in each sample could be determined. 
In the result from NBS, iminodiacetic acid, EDTA, DTPA, and choline, the signal in 
spot B is with the same color and intensity as spot C, suggesting that the amine in sample 
solution did not interfere the result. However, as shown in Figure 2.3b, no dark-bluish 
circle spot could be observed from DMEA’s spot B, and the color of innermost circle 
changed to yellowish. Besides, as shown in Figure 2.3c, the intensity of the circular signal 
from tetrabutylamine was lighter than the reference. As the color and intensity of signal in 
spot B is different from reference, indicating that these amines in sample solution could 
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make interference on the spot test. Furthermore, as the color and intensity is less intense 
than reference, there could be a false-negative result from DMEA and tetrabutylamine.  
 
Figure 2.3 – K2.2.2 reference signal in spot C (a) and K2.2.2 signal in Spot B from 
DMEA (b) and tetrabutylamine (c). 
Moreover, since spot A is from sample without mixed with K2.2.2 solution, the 
possible interference leading to false-positive result could be determined by the 
visualization of dark bluish circle in sample solutions in spot A. By the test on 7 different 
kinds of amine solutions in this study, no dark bluish circle could be observed in spot A. 
Besides, their intensities of signals from spot B were not higher than reference in spot C. 
Therefore, it is suggested that the presence of 7 kinds of amines does not lead to false-
positive results, but DMEA and tetrabutylamine may interfere with K2.2.2 detections by 
leading to a false-negative result. 
To elucidate why DMEA and tetrabutylamine interfere with K2.2.2 detection, while 
the other five amines do not interfere significantly, the pH of the sample solutions was 
measured. The result revealed that the pH of DMEA and tetrabutylamine were higher than 
12.0, while the other amine samples are with a neutral pH (pH = 7.0). This result indicates 
that the pH may contribute to the false-negative results. To further investigate the 
interference of amines without the contribution of pH, the sample solutions of DMEA and 
tetrabutylamine were neutralized to pH=7.0 by citric acid prior to the spot test. It was 
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interesting to find that the color and intensity of their spot B were the same as that of the 
reference in spot C, like other amines with pH=7.0. Therefore, the results indicate that the 
presence of other amines in sample solutions does not contribute to the false-negative result 
of K2.2.2 detection, but that the cause may be the change of pH. 
2.2.3 Interference from the pH 
To investigate the interference from pH, spot tests on non-amine samples with pH 
ranging from 1.0 to 11.5 has been performed. The samples are 0.1 mol/L hydrogen chloride 
(HCl, pH=1.0), 0.1 mol/L trisodium phosphate (TSP, pH=7.5), 0.1 mol/L NaHCO3 
(pH=8.2), and 0.1 mol/L trisodium citrate (pH=11.5).  
As the result from spot A, no dark bluish circle was observed in those samples, 
suggesting that the change of pH does not lead to false-positive results. However, the 
results from spot B were not consistent: spot B’s signals from HCl and TSP were the same 
as K2.2.2 reference in spot C, while that signal from NaHCO3 was lighter than reference, 
even no signal was observed in spot B from trisodium citrate. As a result, HCl (pH=1.0) 
and TSP (pH=7.5) do not interfere with the spot test, but NaHCO3 (pH=8.2) and trisodium 
citrate (pH=11.5) cause the false-negative result. Taking the result from amine test into 
consideration, it is confirmed that the alkali pH causes the interference, and a false-negative 
result can be generated when the pH in sample solution is greater than 8.0. 
2.2.4 Interference from stabilizers commonly used in F-18 FDG synthesis 
As widely used radiolytic stabilizers, ethanol and ascorbic acid are usually added in 
the process of synthesis of F-18 FDG to reduce the self-decomposition of 
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radiopharmaceuticals [153-155]. In this study, the interference from these common radiolytic 
stabilizers has been investigated by testing 0.1% ethanol and 10 mg/mL ascorbic acid with 
neutral pH via spot test. The results of spot A and B from 0.1% ethanol did not show any 
significant change in color or intensity, suggesting that the presence of ethanol does not 
interfere with the spot test. As for test on 10 mg/mL ascorbic acid, however, the color of 
spot A changed to yellowish, as shown in Figure 2.4a. Moreover, the dark bluish circle 
could not be observed in spot B. By pH measurement, the sample solution is neutral 
(pH=7.0). Therefore, the presence of ascorbic acid is most likely to be related to the false-
negative result. 
 
Figure 2.4 – The interference from different concentrations of ascorbic acid. 
Furthermore, the ascorbic acid sample solution has been diluted to 5, 2.5, and 
1.25 mg/mL to investigate the relationship between the interference and the concentration 
of ascorbic acid in the solution. As depicted in Figure 2.4, the intensity of the yellowish 
color is reduced with the decrease of ascorbic acid’s concentration, while the signal of dark 
bluish circle grows more intense in spot B. As shown in Figure 2.4d, the intensity and color 
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of dark bluish circle in spot B becomes the same as reference when the concentration of 
ascorbic acid is 1.25 mg/mL. Therefore, the ascorbic acid in sample solution could also 
lead to a false-negative result. Such interference could be neglected when the concentration 
of ascorbic acid is as low as 1.25 mg/mL. 
As ascorbic acid is a reductant, the staining reagent may be discolored by its 
reducibility. To testify this hypothesis, the interference from another reductant SnSO4 has 
also been tested via spot test. Same results were found as shown in Figure 2.5. The dark 
bluish circle cannot be observed in spot B from samples of saturate SnSO4 in 10% H2SO4, 
and SnSO4 in water. Therefore, it is confirmed that the ascorbic acid, as a commonly used 
radiolytic stabilizer, could generate false-negative results of iodoplatinate staining spot test, 
and the reducibility of ascorbic acid is the reason of the discolor of spot on iodoplatinate 
silica gel plate. 
 
Figure 2.5 – The interference from different concentrations of SnSO4: The dark 
bluish circle cannot be observed in spot B from samples of saturate SnSO4 in 10% 
H2SO4, and SnSO4 in water. 
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2.2.5 Interference from reagents for F-18 FDG synthesis 
Sodium citrate buffer solution (pH=6.0) and 1,3,4,6-tetra-O-acetyl-2-O-triflate-beta-
D-mannopyranose in acetonitrile are main reagents used in the F-18 FDG synthesis. By the 
interference test, no dark bluish circle was observed in spot A, and the signal in spot B 
from each sample is the same with K2.2.2 reference in spot C, suggesting that these 
reagents do not make interference to the spot test. 
Besides, samples of liquids from IC-H, Al2O3, C-18 separation column, and from 
Dowex-50 resins in empty column were also collected and tested by interference 
experiments. Similarly, no interference has been observed from the results. 
2.2.6 System suitability of iodoplatinate staining spot test 
To investigate the system suitability of Iodoplatinate Staining Spot Test, silica gel 
plates from different companies (Macherey-Nager and Whatman) were used and compared 
for K2.2.2 detection at three concentrations (50, 10, and 5 g/mL). As a result, silica gel 
plates from both companies can perform accurate detection of K2.2.2. Meanwhile, the 
K2.2.2 obtained from ABX and Huayi Technology Co., Ltd. has also been compared, 
resulting in a consistent detection outcome. Furthermore, we compared the detection of 
K2.2.2 in F-18 FDG produced by three different synthetic routes that uses K2.2.2. The 
residue of K2.2.2 in F-18 FDG synthesized by HCl hydrolysis[156], liquid phase alkaline 
hydrolysis[157], and alkaline hydrolysis on solid phase support[158, 159] is 5 – 50 g/mL, < 5 
g/mL, and < 5 g/mL, respectively. These results have been confirmed with that resulted 
from iodine-vapor TLC stain method. 
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2.2.7 Detection of K2.2.2 in three batches of F-18 radiopharmaceuticals 
Samples of three batches of F-18 FDG were also spotted on silica gel plates. For the 
result from spot A, no dark bluish circle was observed in samples with batch #20150111, 
#20150114, and #20150105. By the interference test, the signal in spot B from each sample 
is consistent with K2.2.2 reference in spot C, suggesting that the result of spot A would be 
accurate. This indicates the concentration of K2.2.2 in these three batches of F-18 FDG is 
lower than 5 g/mL. These results have been verified by TLC stain method[142]. 
K2.2.2 is the most commonly used phase transfer catalyst for F-18 nucleophilic 
substitution reaction, and there is usually certain residue in the F-18 radiopharmaceuticals. 
Thus, the detection of K2.2.2 residue is an essential analysis for quality control. The 36th 
version of US Pharmacopeia[138] adopts iodine-vapor TLC stain method for K2.2.2 
detection. With this method, the sample is separated by developing agent, therefore getting 
rid of the interference reagents. A high specificity could be achieved by this method. 
However, the procedure of this method is complicated and time consuming, and large 
sample size (0.1 mL for spotting) needed[160]. UV-Vis spectrophotometry is also used for 
K2.2.2 detection, but it takes long time and large amount of sample (0.5 mL for spotting). 
[160] More importantly, it was reported with poor specificity for K2.2.2 detection because 
of the interference from reagents.[161] The European Pharmacopoeia 9.0 version [140] and 
the Chinese Pharmacopoeia 2015 version [139] adopt Iodoplatinate Staining Spot Test for 
K2.2.2 detection, and there are also limitations for the application of this method. K2.2.2 
can react with tertiary amine [149], thus leading to a false-positive or false-negative result. 
If the intensity of K2.2.2 signal exceeds the threshold, it would be necessary to validate the 
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result by iodine-vapor TLC stain method. Therefore, it is important to test the specificity 
of Iodoplatinate Staining Spot Test, prior to apply to routine quality control. 
Results in this study suggest that reagents or fluids from separation columns 
commonly used in F-18 FDG synthesis do not make interference to the detection of K2.2.2 
by Iodoplatinate Staining Spot Test. The results also indicate that Iodoplatinate Staining 
Spot Test is superior to UV-Vis spectrophotometry for K2.2.2 detection as quality control 
in the procedure of F-18 FDG production. Among the amine samples we tested in the 
interfering study, the presence of DMEA and tetrabutylamine significantly interfere with 
K2.2.2 detections, leading to a false-positive result. However, the presence of non-amine 
in alkaline condition (i.e., pH>8.0) also led to the false-positive result. The result of pH 
measurement shows that the pH of DMEA and tetrabutylamine are greater than 12.0. As a 
result, the interference is not likely due to the presence of amine, but relative with the pH 
condition. Therefore, the specificity of Iodoplatinate Staining Spot Test is high when 
pH<8.0. 
Additionally, the sensitivity of Iodoplatinate Staining Spot Test has also been 
investigated in this study. The actual detection limit of K2.2.2 by this method is 5 g/mL, 
which is slightly less sensitive than Mock BH and colleagues’ claim (2 g/mL)[143]. Such 
difference in detection limit may come from the difference concentration of K2PtCl6 and 
KI used for pretreatment of the silica gel plate. This sensitivity is adequate for K2.2.2 
detection, as the maximum permissible level of K2.2.2 residue is 50 g/mL, required by 
the Pharmacopoeia [138-140]. 
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The system suitability of Iodoplatinate Staining Spot Test has been investigated by 
comparisons of different silica gel plates, K2.2.2 reagents and F-18 FDG synthetic methods. 
Confirmed with iodine-vapor stain TLC method, the results of this Iodoplatinate Staining 
Spot Test are reliable and reproducible. 
Based on the results of this study, a rapid K2.2.2 detection protocol is suggested as 
follows. First, measure the pH of the F-18 FDG injection. When the pH<8.0, apply 3 L 
of the injection on iodoplatinate pretreated silica gel plate by micropipette, and observe 
from the spot. If there is no dark bluish circle, the residue of K2.2.2 does not exceed 5 
g/mL; while if a dark bluish circle can be found, further comparison with reference is 
needed. When the pH>8.0, neutralize the alkaline in the injection prior to applying K2.2.2 
detection. 
2.3 Summary 
In this chapter, I demonstrate that the interference from reagents commonly used in 
F-18 pharmaceutical production to spot test of K2.2.2. No false-positive result of spot test 
for detection of K2.2.2 has been observed with the presence of seven different amines or 
other reagents commonly utilized in F-18 radiopharmaceutical synthesis. The interference 
test demonstrated  that the false-negative results are not due to the presence of amines or 
other chemical impurities. However, it was shown that the pH and the presence of ascorbic 
acid could lead to false-negative results. 
The specificity of iodoplatinate staining spot test for K2.2.2 detection has been 
investigated in this study. The detection of K2.2.2 is not interfered by other chemical 
impurities. However, the pH should be lower than 8.0, to make an accurate detection. The 
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lower limit of the detection is 5 g/mL by this method, which is applicable for the test of 
K2.2.2 residue in F-18 FDG injection produced by routes of synthesis that uses K2.2.2. 
Therefore, the iodoplatinate staining spot test is rapid and easy to operate, and sample 
saving (3 L versus 0.1 mL) for routine quality control. 
2.4 Experimental 
2.4.1 Reagents and apparatus 
K2.2.2, AR was purchased from ABX GmbH (Radeberg, Germany) and Huayi 
Technology Co., Ltd. (Jiangsu, China). N, N-dimethylethanolamine (DMEA), choline, and 
tetrabutylammonium (TBA) aqueous solution (1 mol/L) were purchased from Aldrich 
Chemical Co. (Milwaukee, WI, U.S.A.). N-bromosuccinimide (NBS), iminodiacetic acid 
(IDA), ethylenediaminetetraacetic acid (EDTA), trisodium phosphate (TSP), sodium 
citrate, and sodium bicarbonate were obtained from Beijing Chemical Works (Beijing, 
China). Diethylenetriaminepentaacetic acid (DTPA) was acquired from Shanghai Reagent 
First Factory (Shanghai, China). Ascorbic acid was obtained from McGuff 
Pharmaceuticals, Inc (Santa Ana, CA, U.S.A.). SEP-PAK C-18 column and SEP-PAK 
Al2O3 column were acquired from Waters Corp. (Milford, MA, U.S.A.). IC-H column was 
obtained from Grace Alltech (Columbia, MD, U.S.A.). Dowex-50 resins were acquired 
from Bio-Rad Laboratory (Hercules, CA, U.S.A.). 1,3,4,6-tetra-O-acetyl-2-O-triflate-beta-
D-mannopyranose was obtained from Huayi Technology Co., Ltd. (Jiangsu, China). SnSO4 
was purchased from Xiya Reagent (Chengdu, China). Potassium hexachloroplatinate 
(K2PtCl6) and potassium iodide (KI) were acquired from JK Chemical (Beijing, China). 
0.2 mm Polygram® polyester sheets SIL G were obtained from Macherey-Nager (Dueren, 
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Germany). Flexible plates for TLC, PE Sil G/UV, were obtained from Whatman 
(Buckinghamshire, UK). Canon EOS 40D with an EF 100 mm f/2.8 USM lens was 
acquired from Canon (Tokyo, Japan). 
2.4.2 Gel plate preparation 
Iodoplatinate staining silica gel plate was prepared in accordance with the guidance 
from Chinese Pharmacopoeia [139]: 3 mL of 100 g/L K2PtCl6 solution was diluted in 97 mL 
of water, then mixed with 100 mL of 60 g/L KI solution. Silica G plates were immersed in 
this K2PtCl6 and KI mixed solution for 5 – 10 seconds, then dehydrated in dark place in 
room temperature for more than 12 hours. 
2.4.3 TLC analysis 
Stock standard solution of 100 g/mL K2.2.2 was prepared in water for injection 
(WFI). 3 L of the following solutions were spotted on the iodoplatinate pretreated silica 
gel plate by micropipette: 
Spot A: sample solutions alone; 
Spot B: sample solutions mixed with K2.2.2 standard solution in a relation of 1:1 (v/v); 
Spot C: 50 g/mL K2.2.2 solution: 100 g/mL K2.2.2 standard solution mixed with 
water for injection (WFI) in a relation of 1:1 (v/v). 
The plates were then photographed by the Canon EOS 40D camera 10 min after 
spotting for visual analysis. 
 36 
2.4.4 Three batches of F-18 FDG synthesis 
Three batches of F-18 FDG were synthesized by solid phase extraction method we 
reported in previous work[158]. In short, F-18 ion in cyclotron was captured by QMA 
column, then washed with sodium carbonate solution containing K2.2.2 and dehydrated in 
tube. The 1,3,4,6-tetra-O-acetyl-2-O-triflate-beta-D-mannopyranose was dissolved in 
acetonitrile then added to the tube, an intermediate could be produced afterwards. After 
adsorbed by C-18 column, the intermediate was hydrolyzed by sodium hydroxide (NaOH) 
solution. After purification by IC-H column, Al2O3 column, C-18 column, and sterile 
membrane, the F-18 FDG injection was produced. 
2.4.5 Sample solutions 
Sample #1 – #4 are liquid collected from separation column. Sample #5 and #6 are 
reagents commonly used in the synthesis of F-18 FDG as shown in Error! Reference 
source not found.. 





Table 2.2. Among them, NBS, IDA, and EDTA are divalent amines; DTPA and 
DMEA are trivalent amines; choline and TBA are tetravalent amines. 
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Sample #14 – #17 are non-amine solution with different pH as shown in Table 2.3, 
with pH ranging from 1.0 to 11.5. 
Sample #18 – #22 are radiolytic stabilizer solutions as shown in Table 2.4. Ethanol 
and ascorbic acid are commonly used stabilizer when synthesizing F-18 
radiopharmaceuticals. 
Table 2.1 – Sample #1 – #6: reagents commonly used in the synthesis of F-18 FDG 
and liquid collected from separation column. 
Sample ID Volume Sample information 
Sample #1 2 mL 
Wash the IC-H column with 2 mL of WFI, then collect the 
washing fluids. 
Sample #2 10 mL 
Wash the Al2O3 column with 10 mL of WFI, then collect the 
washing fluids. 
Sample #3 10 mL 
Wash the C-18 column with 10 mL of WFI, then collect the 
washing fluids. 
Sample #4 10 mL 
Install 1.5 g of Dowex-50 resins into empty column, then 
wash with 10 mL WFI and collect the washing fluid. 
Sample #5 10 mL 10 mL of 0.5 mol/L sodium citrate buffer at pH=6.0. 
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Sample #6 10 mL 
Dissolve 20 mg of 1,3,4,6-tetra-O-acetyl-2-O-triflate-beta-D-
mannopyranose with 2 mL of Acetonitrile, then dilute in 8 






Table 2.2 – Sample #7 – #13: different types of amine solution. 
Sample ID Concentration Sample information 
Sample #7 1 mg/mL N-bromosuccinimide (NBS) aqueous solution 
Sample #8 1 mg/mL Iminodiacetic acid (IDA) aqueous solution 
Sample #9 1 mg/mL Ethylenediaminetetraacetic acid (EDTA) aqueous solution 
Sample #10 1 mg/mL 
Diethylenetriaminepentaacetic acid (DTPA) aqueous 
solution 
Sample #11 1 mg/mL N, N-dimethylethanolamine (DMEA) aqueous solution 
Sample #12 1 mg/mL Choline aqueous solution 
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Sample #13 0.1 mol/L tetrabutylammonium (TBA) aqueous solution 
Table 2.3 – Sample #14 – #17: non-amine solution at different pH conditions. 
Sample ID Concentration Sample information 
Sample #14 0.1 mol/L Hydrochloric acid (HCl), pH=1.0 
Sample #15 0.1 mol/L Trisodium phosphate (TSP), pH=7.5 
Sample #16 0.5 mol/L NaHCO3, pH=8.2 
Sample #17 0.1 mol/L Trisodium citrate, pH=11.5 
Table 2.4 – Sample #18 – #22: radiolytic stabilizer solutions with different pH. 
Sample ID Concentration Sample information 
Sample #18 0.1% Ethanol 
Sample #19 10 mg/mL Ascorbic acid 
Sample #20 5 mg/mL Ascorbic acid 
Sample #21 2.5 mg/mL Ascorbic acid 




CHAPTER 3. F-18 ML-10 IMAGING FOR SAFETY 
ASSESSMENT OF RADIOTHERAPY 
The safety assessment early after treatment is important for disease management, 
especially for patients with malignant tumor. In last chapter, the application of F-18 ML-
10 in assessment of radiotherapy of brain tumor has been investigated. However, there is 
no report of applying F-18 ML-10 to assess the radiotherapy of lung cancer. In this chapter, 
a special case for therapeutic assessment on lung cancer is reported. By this case study, the 
early safety assessment of radiation by the F-18 ML-10 apoptosis imaging has been first 
applied to lung cancer, and the result of this assessment is consistent with that of traditional 
evaluation. Furthermore, the side effect of CyberKnife (CK) radiotherapy has also been 
discussed. However, the apoptosis in heart tissue and aortic arch increased significantly, 
indicating a damage on heart tissue and smooth muscle in aortic arch by CK treatment. By 
animal studies, the subsidiary injury in heart tissue after radiation was observed by 
apoptosis imaging. Therefore, the CK treatment in this case could cause subsidiary-injury 
of heart tissue, due to a rapid apoptotic response from heart tissue after radiotherapy, and 
the F-18 ML-10 apoptosis imaging shows the potential to assess and guide the radiotherapy 
early after therapy and between fractions. 
3.1 Introduction 
For radiotherapy and chemotherapy, there is always a serious lag effect for the 
evaluation the therapeutic due to lack of the assessment based on rapid biological response, 
resulting in a delay or loss of chance for an alternative treatments [12-14]. 
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Molecular imaging visualizes real-time biological process in cellular and molecular 
level by molecular probes. The development of molecular imaging makes early therapeutic 
assessment of radiotherapy feasible. As one of molecular imaging methods, apoptotic 
imaging could evaluate the early therapeutic response by providing dynamic apoptotic 
information after radiation, because radiotherapy cures cancer mainly by inducing 
apoptosis [25, 29, 162]. F-18 ML-10, is the first clinically available apoptosis probe for in vivo 
imaging [135]. The F-18 ML-10 can be transported through cytoplasmic membrane in 
apoptotic cells, whereas there is no F-18 ML-10 membrane transportation in necrotic cells, 
providing an imaging tool to distinguish apoptosis from necrosis [27]. Although having been 
used to assess the outcome of radiotherapy for brain tumor for couple of years [9, 19, 20, 22], 
the F-18 ML-10 has hardly ever been applied to therapeutic assessment for tumor on other 
sites. 
In this chapter, a special case for therapeutic assessment on lung cancer is reported. 
By this case study, the application of F-18 ML-10 on lung cancer has been investigated. 
Furthermore, the side effect of Cyber-Knife (CK) radiotherapy has also been discussed.  
3.2 Results and discussion 
3.2.1 Subject and image registration 
The subject included in this study was 76 years old male with lung cancer, scheduled 
to undergo CK stereotactic radiotherapy. F-18 ML-10 PET/CT images has been obtained 
before and 48 hours after the CK radiotherapy. As the patient’s position of two scans 
changed and the lack of feature points in CT, the registration by MIM software gave a poor 
accuracy. 
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As a result shown in Figure 3.1, in the subtraction result, the reddish area represents 
the higher apoptosis, whereas the bluish area represents the lower apoptosis. However, the 
contour of the body showed reddish, while noisy heterogeneous signal was observed in the 
lung. Therefore, other method should be used to make a precise registration. In this study, 
two methods have been used for registration of the images to analyze the change of 
apoptosis before and after the radiotherapy. 
 
Figure 3.1 – Registration and analysis by MIM 6.6.5 software. 
As the PET/CT scanning gives registered PET and CT images for once scanning, we 
can achieve the registration of PET images by registering their CT images before and after 
CK radiotherapy. As shown in Figure 3.2, the CT images in each slide has been registered 
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between the baseline (before CK radiotherapy) and the early therapy assessment (48 hours 
after CK radiotherapy). 
 
Figure 3.2 – Registration of CT images in each slide before and 48 hours after CK 
radiotherapy. 
 
Figure 3.3 – Registration of CT images before (a) and 48 hours after (b) CK 
radiotherapy with detail features as indicated by cyan stars. 
The advantage of this method is that the CT image could give a more accurate 
registration by detail features (see Figure 3.3), while the PET images cannot reach this high 
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resolution. However, by this registration method, we need to perform three times 
registration to get two registered PET images. In specific, the CT images before and after 
CK should be registered as introduced before, then the PET images would be registered 
with their own CT images. Finally, the PET images could be registered with the location 
markers from previous registration. In these processes, the error could be induced in the 
registrations. At this situation, we also adopted another method for the direct registration 
of PET images. 
 
Figure 3.4 – Direct registration of PET images before (a) and 48 hours after (b) CK 
radiotherapy. 
Although the features in PET images are limited comparing with that in CT images, 
it is sufficient for the registration of PET images, and the accuracy is even higher than the 
indirect registration we proposed in last paragraph. Therefore, the direct registration of PET 
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images of different slides has been adopted for the registration of this case. Furthermore, 
the PET images have been normalized based on the radioactive dosages. 
3.2.2 High apoptosis in heart tissue 
 
Figure 3.5 – The change in radioactivity from heart tissue before and after CK 
radiotherapy: (a) CT image before CK; (b) PET image before CK; (c) CT image after 
CK; (d) PET image after CK; and (e) subtraction of PET images. 
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By the analysis of the registered PET images before and early after CK radiotherapy, 
the change of apoptosis activity in the region of interest (ROI) was visualized by the change 
of radioactivity in the image. 
As shown in Figure 3.5, the registration of PET image has been confirmed with the 
CT image for each slide (see Figure 3.5a and Figure 3.5b). Interestingly, the change in 
radioactivity from heart tissue overwhelms that from tumor area, as indicated in Figure 
3.5c and Figure 3.5d. With the calculation of radioactivity, the apoptotic activity changed 
to 3.279 times higher after CK therapy, as shown in cyan color area in Figure 3.5e. It is 
indicated that the heart tissue was damaged by the radiotherapy, while the apoptosis of 
tumor tissue does not change significant. 
3.2.3 Recurrence of lung tumor 
By the analysis of apoptosis imaging, the apoptosis of tumor tissue was not 
significantly changed, indicating that there may not be a rapid response of the tumor after 
the CK radiotherapy. According to the return visit of the patient one year after the CK 
radiotherapy, the result showed a recurrence of the tumor in the same site. Therefore, the 
result of early assessment of the radiotherapy by F-18 ML-10 apoptosis imaging is 
consistent with the therapeutic assessment one year afterwards.  
As shown in the CK treatment plan in Figure 3.6, though it was focused on the tumor 
in left lung, the heart tissue and aortic arch also received dosage from this therapy. As the 
aortic arch and heart are usually treated as “blood pool”, the signal could be influenced by 
the F-18 ML-10 in blood stream. In this study, the PET/CT imaging was scanned 90 
minutes after the injection, which is longer than the F-18 ML-10 clearance ratio. Therefore, 
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the influence of F-18 ML-10 in blood could be eliminated in this study, and the signal are 
likely from the high uptake of the tissues accordingly. To verify this hypothesis from the 
results in this case study, an animal study was designed to investigate the subsidiary-injury 
of heart tissue induced by radiation. 
 
Figure 3.6 – Plan of CK radiotherapy. 
3.2.4 Evaluation of subsidiary-injury of lung cancer radiotherapy  
To evaluate the subsidiary-injury induced by lung cancer radiotherapy, a rabbit model 
has been developed according to the CyberKnife plan shown in Figure 3.6. As the detail 
plan shown in Figure 3.7, the total dose was 50 Gy, and the total fractions are 5, and the 
bioequivalent dosage was 100 Gy. In the radiotherapy of tumor in lung tissue or adjacent 




Figure 3.7 – Plan information of CK radiotherapy. Prescription dose was 50 Gy, with 
5 fractions. 
In this rabbit model, the heart tissue received radiation with different dosage, then F-
18 ML-10 imaging was obtained 24 hours after the radiation. Registration of heart tissue 
has been scanned by CT prior to the radiation, and the setup of the radiation for rabbit is 
shown in Figure 3.8. 
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Figure 3.8 – Registration of heart tissue for rabbit radiation. 
 
Figure 3.9 – F-18 ML-10 PET/CT imaging of control rabbit (i.e., without 
radiotherapy). The average SUV in ROI is 0.25. 
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The result of F-18 ML-10 PET/CT imaging of control rabbit is shown in Figure 3.9. 
In this PET imaging, the F-18 ML-10 signal from heart tissue has been circled as the ROI. 
The mean SUV measured in ROI is 0.25. In the control group, the average SUV of five 
rabbits in control group is 0.22. 
 
Figure 3.10 – F-18 ML-10 PET/CT imaging of rabbit 24 hours after radiotherapy 
with 20 Gy radiation. The average SUV in ROI is 1.30. 
In one of the experimental groups, the rabbits received 20 Gy radiation, and then 
scanned 24 hours after radiotherapy. As the result shown in Figure 3.10, the mean SUV in 
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ROI is 1.30, and the average of two rabbits in this experimental group is 1.24. Comparing 
with the control group, a very significant increase (p < 0.01) of the apoptosis was induced 
by the radiation of 20 Gy, and such radiation may induce subsidiary-injury of heart by lung 
cancer therapy by a rapid apoptosis response.  
 
Figure 3.11 – F-18 ML-10 PET/CT imaging of rabbit 24 hours after radiotherapy 
with 10 Gy radiation. The average SUV in ROI is 0.37. 
Moreover, in another experimental group, we decreased the dosage of radiation to 10 
Gy, to visualize the change in apoptosis early after the radiation with lower dosage. As 
 52 
shown in Figure 3.11, the mean SUV in ROI is 0.37 from one of the rabbits 24 hours after 
10 Gy radiation, and the average of three rabbits in this experimental group is 0.35. By 
comparing with the control group, the average apoptosis is higher after the radiation, but 
no statistically significant difference could be found, p = 0.10. 
By statistical analysis on the apoptotic change in F-18 ML-10 PET imaging, the result 
of quantification of the apoptotic change in SUV is shown in Figure 3.12. The signal in 
ROI from the group of rabbits received 20 Gy radiation became significantly higher than 
the control group, suggesting that the rapid apoptosis response could be induced in 
radiotherapy when the dose of heart is as high as 20 Gy. The PET results from rabbits 
received 10 Gy radiation indicate that 10 Gy radiation on heart tissue may not induce rapid 
apoptosis in this study.  
 
Figure 3.12 – Comparison on SUV of F-18 ML-10 PET imaging after 10 and 20 Gy 
radiation. 
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Therefore, the animal study provides more evidence to visualize the subsidiary-injury 
of lung cancer therapy by F-18 ML-10 PET imaging. Furthermore, the F-18 ML-10 shows 
its potential to guide the radiotherapy between fractions, by evaluating the apoptosis 
response and the subsidiary-injury of heart induced by radiation. 
3.3 Summary 
In this chapter, the early assessment of therapeutic response by the F-18 ML-10 
apoptosis imaging has been first applied to lung cancer, and the result of this assessment is 
consistent with that of traditional evaluation. After CK treatment, there was no significant 
change in the apoptosis of tumor. However, the apoptosis in heart tissue and aortic arch 
increased significantly, indicating a damage on heart tissue and smooth muscle in aortic 
arch by CyberKnife treatment. An animal study provides more evidence to the subsidiary-
injury of lung cancer therapy by visualization of apoptosis response from F-18 ML-10 PET 
imaging. Therefore, this study suggests that CK treatment could cause subsidiary-injury of 
heart tissue, by inducing a rapid apoptosis of heart tissue after radiotherapy. Therefore, it 
is suggested to protect the heart tissue from the radiation due to its rapid apoptotic response. 
3.4 Experimental 
3.4.1 Informed consent and statement of human rights 
Informed consent was obtained from all participants. All protocol of this clinical study 
has been approved by Institutional Review Board of Chinese PLA General Hospital 
3.4.2 PET/CT acquisition protocol 
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PET/CT imaging were performed before and 48 hours after CK therapy with AMIC 
Ray-Scan 64 PET/CT system (AMIC, Beijing, China), 90 minutes after F-18 ML-10 tracer 
injection with 0.12 mCi/kg b. w. The F-18 ML-10 tracer was produced at the Department 
of Nuclear Medicine at PLAGH PET Facility [163] with PET-MF-2V-IT-I Fluorine 
multifunctional synthesis module (PETKJ, Beijing, China), and the radiochemical purity 
is of >98% by HPLC.  
PET images were acquired by three-dimensional brain mode, with 2.5-mm slice width, 
512 × 512 reconstruction matrix. CT images were acquired with a 50-cm field of view 
(FOV), 75-cm diameter of gantry, 2.5-mm of slice width, 150-cm maximum positioning 
length, 175-cm axial moving range of patient bed, and 512 × 512 of reconstruction matrix. 
3.4.3 CT acquisition protocol 
CT images for localization of tumor were acquired on Brilliance TM (Philips 
healthcare, Amsterdam, Netherland), with an 80-cm maximum field of view (FOV), 60-
cm actual FOV, 85-cm diameter of gantry, 1.5-mm of slice thickness, 150-cm maximum 
positioning length, 190-cm axial range of patient bed, and 1024 × 1024 of maximum 
reconstruction matrix. 
3.4.4 Radiotherapy protocol 
CyberKnife which enables stereotactic radiosurgery delivery applied in this study was 
manufactured by Accuray (Accuray Inc., Sunnyvale, CA, USA). Non-isocentric treatment 
plan was implemented through accelerator mounted on the robotic arm with continuous 
real-time image-guided technology. 
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The blood, urine as well as biochemical examination, electrocardiography (ECG) and 
chest X-ray was acquired before. After enrolment, patient underwent head CT and MRI 
scanning for location of tumor. The acquired CT images was co-registered with MRI 
images by MIM software (version number: 6.5.4), which was imported into CyberKnife 
Robotic Radiosurgery System (Multiplan 4.0.2) for target and organs at risk delineation. 
With the information provided by the fused images, the target area of CK treatment was 
optimized and the gross tumor volume (GTV) was recorded by radiologists and physicians. 
Patients underwent CK stereotactic radiosurgery with 6D⁃skull tracking, and the treatment 
scheme was with 10 Gy in 5 fractions according to the tumor size and position. 
3.4.5 In vivo animal studies 
We performed studies on seven 2.8 – 3.0 kg male rabbits. Two rabbits underwent 20 
Gy radiation by Elekta SynergyTM S linear accelerator, three rabbits underwent 10 Gy 
radiation by the same system, while five rabbits are in control group. 3 mCi of F-18 ML-
10 was injected via auricular vein 24 hours after the radiation. PET/CT scanning was 
performed 60 minutes after injection of F-18 ML-10. The protocol of animal study has 
been approved by Institutional Review Board of Chinese PLA General Hospital. 
3.4.6 Statistical analysis 
For statistical analysis, two-tail paired Student’s t-tests were applied to analyze the 
change in radioactivity before and after treatment, and p < 0.05 was considered as 
statistically significant.
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CHAPTER 4. F-18 ML-10 IMAGING FOR EFFICACY 
ASSESSMENT OF APOPTOSIS RESPONSE OF INTRACRANIAL 
TUMOR EARLY AFTER RADIOTHERAPY 
As discussed in last chapter, the removal and detection of K2.2.2 in the synthesis 
process of F-18 ML-10 has been demonstrated. In this chapter, I demonstrate the clinical 
use of F-18 ML-10 to assess the apoptosis response of intracranial tumor early after 
CyberKnife (CK) treatment. As F-18 ML-10 is a novel apoptosis molecular probe, limited 
clinical studies has been investigated on F-18 ML-10. In the clinical use, there are many 
challenges for quantitative analysis of therapeutic assessment by using apoptotic imaging. 
As apoptosis is essentially a transient process, it is necessary to standardize the imaging 
method and time point, and to make quantitative analysis based on “volume-by-volume” 
of the image, to distinguish between cell apoptosis and spontaneous apoptosis. 
In this chapter, a pilot study on 29 human subjects diagnosed with intracranial tumors 
were included in this study. Clinical data of different types of brain tumor have been 
collected, and the PET image has been analyzed volume-by-volume in assessment of 
response of different types of tumors to radiotherapy. Furthermore, correlation between the 
result of this early assessment and subsequent anatomic change in tumor determined by 
MRI was also investigated for the further safety and effectiveness assessment. 
A positive correlation was observed between the change in F-18 ML-10 uptake in the 
tumor measured during early treatment and the subsequent change in tumor volume 
measured after the completion of CK treatment. Malignant tumors tend to be more sensitive 
to CK treatment, but the treatment outcome is not affected by pre-CK apoptotic status of 
tumor cells, F-18 ML-10 PET imaging could be taken as an assessment tool within 48 
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hours after CK treatment. By analyses on the application of this method on different 
patients, the result indicates that the F-18 ML-10 early assessment may give a more 
accurate evaluation early after radiotherapy. 
4.1 Introduction 
Intracranial and central nervous system (CNS) tumors are of high incidence in 
adolescents (0-19 years). In the U.S., the average age-adjusted incidence is annually 5.57 
per 100,000 population from 2008 to 2012, and nearly 700,000 people live with intracranial 
and CNS tumors [17]. In the past decades, the overall diagnostic rate of intracranial tumor 
has been raised by the development of diagnostic imaging technologies, such as X-ray 
computed tomography (CT) and magnetic resonance imaging (MRI). Nowadays, the most 
common radical cancer treatments are surgery, radiotherapy and chemotherapy. And 
radiotherapy is an important method for intracranial treatment that could either be a main 
regiment, or adjuvant therapy after surgery for keeping cancer from recurrence. The 
evaluation of therapeutic response mainly relies on the change of tumor size assessed by 
CT and MRI images. For radiotherapy and chemotherapy, however, the anatomical volume 
change comes later than the rapid biological change on cellular level, resulting in a serious 
lag effect for the evaluation [9]. Indeed, the anatomical volume change of intracranial tumor 
is difficult to be visualized by CT or MRI till 4-8 weeks after whole brain radiotherapy [10, 
11]. Particularly, for patients with malignant brain tumor, such as high-grade gliomas and 
metastatic tumors, etc., the average survival time is short. With the lag effect of 
conventional assessments, the early response after radiotherapy is hard to be assessed 
which might result in a delay or loss of chance for an alternative treatments [12-14]. Moreover, 
the tumor tissue and radio-necrotic tissue could not be distinguished by CT and MRI 
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images, which might cause ambiguous or even wrong judgment of therapeutic effect. 
Therefore, a method which could offer an early response assessment after radiotherapy for 
clinical management improvement is required. 
Molecular imaging visualizes real-time biological process in cellular and molecular 
level by molecular probes. The development of molecular imaging makes early therapeutic 
assessment of radiotherapy feasible. As one of molecular imaging methods, apoptotic 
imaging could evaluate the early therapeutic response by providing dynamic apoptotic 
information after radiation, because radiotherapy cures cancer mainly by inducing 
apoptosis [25, 29, 162]. In the past decade, molecular imaging modalities such as PET/CT, 
MRI, magnetic resonance spectroscopy (MRS), B- Ultrasound and diffuse optical 
tomography (DOT), etc. have been developed and widely used. Among these modalities, 
only PET/CT could accurately provide quantitative information of apoptosis with proper 
apoptosis probe at molecular level. 
Currently, three types of widely used apoptosis probes are proteins, non-specific small 
molecules and caspase activation. However, the limitations such as poor specificity, slow 
blood clearance and immunogenicity etc. impede these probes’ clinical applications. An 
ideal apoptosis probe for clinical practice should be specific for apoptotic cells, with rapid 
clearance, nontoxic, and high stable [28, 133, 134]. F-18 labeled 2-(5-fluoropentyl)-2-methyl 
malonic acid (F-18 ML-10), a low-molecular mass (molecular weight = 206) PET apoptotic 
tracer derived from Aposense family, is the first clinically available apoptosis probe for in 
vivo imaging. Being investigated in multi-center preclinical and clinical trials, F-18 ML-
10 shows high stability, safety, specificity, and rapid biodistribution [22, 23]. As a probe to 
visualize cell apoptosis in vivo, F-18 ML-10 selectively accumulates in apoptotic cells by 
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recognizing alterations on the surface of apoptotic cells [19, 20], thus the apoptotic cells could 
be distinguished from normal cells. Additionally, F-18 ML-10 could be transported 
through cytoplasmic membrane in apoptotic cells, whereas there is no F-18 ML-10 
membrane transportation in necrotic cells. Therefore, we are able to distinguish apoptosis 
from necrosis[27]. 
In this study, we investigated the performance of early response after CyberKnife (CK) 
stereotactic treatment on 29 patients with intracranial tumors, through F-18 ML-10 
PET/CT imaging with voxel-by-voxel analysis. Furthermore, the correlation between the 
result of this early assessment and subsequent anatomic change in tumor determined by 
MRI was also investigated for the further safety and effectiveness assessment. 
4.2 Results and discussion 
4.2.1 Subjects and lesions information 
In this trial, 33 patients aged from 22 to 69 years old, with 34 lesions were included. 
29 patients with 30 lesions completed the trial. Among the 30 lesions, there are 12 
metastatic neoplasms (in 11 subjects), 6 meningiomas, 3 cavernous hemangiomas, 3 germ 
cell tumors, 2 hemangiopericytomas, 2 adenoid cystic carcinomas, 1 chordoma, and 1 
hypophysoma. The 29 patients who completed the trial were with no radiation-related 
complication occurred. 
4.2.2 Visualization and analysis of apoptotic imaging of intracranial tumor 
The result of F-18 ML-10 PET/CT apoptosis imaging (Figure 4.1) shows a high PET 
signal from spontaneous apoptosis in the lesion area, while the signal in surrounding 
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normal brain tissue is relatively low. Thus, the location and extent of the tumor could be 
identified in PET/CT images. 
 
Figure 4.1 – Representative PET/CT F-18 ML-10 image of a male patient, 48 years 
old, diagnosed with kidney cancer brain metastases, pre-CK. 
 
Figure 4.2 – Pre-CK PET/CT image (a) and post-CK PET/CT image (b) of a female 
patient, 61 years old, diagnosed with lung cancer brain metastases, showing an 
obvious and uniform increase of F-18 ML-10 uptake 
The change in F-18 ML-10 uptake between pre-CK (Figure 4.2a) and post-CK (Figure 
4.2b) is analyzed by a voxel-wise method. As shown in Figure 4.2a and Figure 4.2b, the 
post-CK uptake of ML-10 tracer is clearly higher than pre-CK uptake. In other cases, 
however, there is obscure difference of F-18 ML-10 uptake between pre-CK (Figure 4.3a) 
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and post-CK (Figure 4.3b). As clear change in F-18 ML-10 uptake cannot be visualized by 
the PET/CT images, the subtraction of “post-CK” – “pre-CK” (Figure 4.3c) is processed 
by MIM software, with a reference of GTV information as the red contour of tumor. With 
this subtraction analysis shown in Figure 4.3c, a greater change in the F-18 ML-10 was 
found in the central area of the tumor, rather than the edge, suggesting that there are more 
apoptotic cells at the center while less apoptotic cells at the edge after CK treatment. In this 
case, an intuitive and clear change in the apoptotic tumor cells could be visualized by the 
change in F-18 ML-10 uptake with subtraction of PET images. Moreover, the area with 
high PET signal corresponded well with the lesions determined by GTV and MRI fused 
image (Figure 4.3d). 
The analysis based on subtraction enables the judgement of whether there is more or 
less apoptosis happening in ROI after CK treatment feasible. However, the heterogeneous 
and two-way overall changes of tracer uptake cannot be revealed by subtraction analysis. 
As shown in Figure 4.4, some portion of the tumor becomes more apoptotic, while the 
other becomes less apoptotic, and there is unchanged portion remains. Therefore, 
quantitative analysis of the voxel-based subtraction is needed to further investigate cases 
with heterogeneous and two-way changes. 
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Figure 4.3 – Pre-CK PET/CT image (a), post-CK PET/CT image (b), subtraction (c) 
of PET image, and fused PET/MRI images (d) of a female patient, 54 years old, 
diagnosed with Cavernous hemangioma in cavernous sinus. Red line indicates the 
contour of tumor. The color bar shown in (d) corresponds to radioactivity changing 
ratio. 
4.2.3 Quantitative analysis for accurate subtraction 
With the registration and fusion of pre-CK and post-CK PET images, the change in 
F-18 ML-10 uptake in radioactivity after CK treatment of each voxel in ROI could be 
extracted and sorted into one of the following three categories: (1) voxels with increased 
F-18 ML-10 uptake, defined as a positive change in radioactivity of more than 12.5% from 
pre-CK, representing cells in early apoptosis; (2) voxels with decreased F-18 ML-10 uptake, 
defined as a negative change in radioactivity of more than 12.5% from pre-CK, 
representing vascular occlusion and/or clearance of apoptotic cells; (3) voxels without 
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change in F-18 ML-10 uptake, defined as a change in radioactivity of less than 12.5%. 
Wherein, the threshold of 12.5% is set in accordance with references [9, 164]. 
 
Figure 4.4 – Pre-CK PET/CT image (a), post-CK PET/CT image (b), subtraction (c) 
of PET image, and fused PET/MRI images (d) of a male patient, 21 years old, 
diagnosed with germ cell tumor. Color bar shown in (d) corresponds to radioactivity 
changing ratio. The change in tracer uptake from pre-CK (a) to post-CK (b) is 
visualized by the subtraction of PET images (c) and PET/MRI images (d). 
As the change in apoptosis could not be accurately quantified by average change in 
radioactivity due to the heterogeneity of tumor tissue, the signal change in each voxel in 
ROI is plotted into scatter graph (Figure 4.5), with pre-CK’s radioactivity on the X-axis, 
and the post-CK’s radioactivity on the Y-axis. Voxels with increased signal are shown in 
red, representing increased apoptotic activities, voxels with decreased signal are shown in 
blue, while voxels with unchanged (change less than ±12.5%) signal are shown in green.  
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Figure 4.5 – Voxel-based subtraction scatterplots showing the effect of CK treatment 
in a subject with positive apoptotic response (a) and a subject without significantly 
apoptotic response (b). The X-axes represent the pre-CK radioactivity, while the Y-
axes represent post-CK radioactivity. Voxels with increased signal are shown in red, 
representing increased apoptotic activities. Voxels with decreased signal are shown in 
blue, and voxels with unchanged (change less than ±12.5%) signal are shown in green. 
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The response of radiotherapy could be classified into different types, by the 
comparison of different subjects’ signal changing pattern depicted in scatterplots (Figure 
4.5a and Figure 4.5b).The change in tumor size for all 30 lesions from 29 subjects was 
obtained by MRI 2 to 4 months after CK treatment completion, and the mean percentage 
of volume change was 30.96%±21.73% (95% CI 22.85% – 39.08%) reduced in tumor 
size. In the meanwhile, the mean change per voxel was 32.03%±18.40% (95% CI 25.16% 
– 38.90%). As correlation analysis shown in Figure 4.6, a significant correlation was 
observed between the change in F-18 ML-10 uptake (X) and subsequent change in tumor 
volume (Y) with a Pearson correlation coefficient R = 0.862, p < 0.05. The linear regression 
equation is: Y = 1.018 * X − 0.016. T-test result of the regression coefficient is: t = 9.010, 
p <0.05, and ANOVA result of the regression coefficient is: F = 81.175, p < 0.05. 
 
 
Figure 4.6 – Correlation between the change in F-18 ML-10 uptake (X) and 
subsequent change in tumor volume (Y). The Pearson correlation coefficient is R = 
0.862, p < 0.05. 
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4.2.4 Comparison of the therapeutic response in different cancer type 
 
Figure 4.7 – The comparison of therapeutic response in benign and malignant tumors. 
A significant difference of the radioactivity change (a) between malignant and benign 
tumor has been observed, p = 0.0258. Furthermore, this difference is confirmed by 
subsequent volume change (b) with statistical significance, p = 0.0262. 
As shown in Figure 4.5a, the number of voxels with increased apoptosis indicated by 
red spots overwhelms that of decreased and unchanged signal, showing that positive 
apoptosis has been increased in tumor area by SRS, thus suggests an effective radiotherapy. 
However, for the other case shown in Figure 4.5b, no significant change in apoptotic signal 
could be defined as an increase or decrease by the scatterplot result. Therefore, the 
individual response early after radiotherapy could be revealed by quantitative scatterplot 
of apoptotic change, especially for heterogeneous change. Moreover, Moffat et al assessed 
the effectiveness by correlating the early apoptotic change and the subsequent change in 
tumor volume [164]. 
In accordance with 2016 World Health Organization’s (WHO) classification of CNS 
tumors, 30 lesions in this study could be classified into 2 groups: 18 malignant and 12 
benign tumors. The changes in radioactivity and subsequent tumor volume of each lesion 
have been analyzed, and the comparison in different cancer type are shown in Figure 4.7. 
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As depicted in Figure 4.7a, a significant difference of the radioactivity change between 
malignant and benign tumor has been observed, p = 0.0258. Furthermore, this difference 
is confirmed by subsequent volume change with statistical significance (see Figure 4.7b), 
p = 0.0262. Therefore, malignant tumors could be considered to be more sensitive to CK 
treatment in comparison with benign tumors.  
 
Figure 4.8 – The comparison of the F-18 ML-10 assessment in patients with malignant 
(blue) and benign (red) tumor. The F-18 ML-10 assessment on patients with 
malignant shows a better linear correlation between tumor volume change and 
changes in radioactivity early after radiotherapy. 
Furthermore, the analysis on the F-18 ML-10 assessment in patients with malignant 
(blue) and benign (red) tumor has been conducted. As shown in Figure 4.8, the F-18 ML-
10 assessment on patients with malignant shows a better linear correlation between tumor 
volume change and changes in radioactivity early after radiotherapy. The R square of F-18 
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ML-10 assessment on malignant tumors is 0.9561, whereas it is 0.4201 for assessment on 
benign tumors. Therefore, this suggests that malignant tumors are more sensitive to 
radiotherapy by inducing more apoptosis in the tumor area, and the F-18 ML-10 assessment 
may give a more accurate evaluation on radiotherapy of patients with malignant tumors. 
 
Figure 4.9 – The comparison of therapeutic response in high pre-CK radioactivity 
and low pre-CK radioactivity tumors. No significant difference in radioactivity 
change (a, p = 0.5640), or subsequent volume change (b, p = 0.7226) was found 
between these two groups. 
Among all lesions included in this study, there are 16 lesions with high pre-CK 
radioactivity value, while 14 lesions with lower radioactivity before CK treatment, with 
the threshold of 10,000 Bq/mL. The comparison of therapeutic response between high pre-
CK and low pre-CK groups was conducted. As shown in Figure 4.9a and Figure 4.9b, there 
is no significant difference in radioactivity change (p = 0.5640), or subsequent volume 
change (p = 0.7226) between these two groups after CK treatment. Furthermore, the F-18 
ML-10 assessment between these two subgroups of patients has been compared as shown 
in Figure 4.10. Therefore, this suggests that the pre-CK radioactivity does not influence the 




Figure 4.10 – The comparison of the F-18 ML-10 assessment in patients with pre-CK 
radioactivity higher than 10,000 Bq/mL (blue) and lower than 10,000 Bq/mL (red). 
The F-18 ML-10 assessment on this two groups of patients does not show significant 
difference in the linear correlation between tumor volume change and changes in 
radioactivity early after radiotherapy. 
4.2.5 Evaluation on applicability of the F-18 ML-10 therapeutic response by different 
subgroups of patients 
In order to further analyze the applicability of F-18 ML-10 early assessment of 
therapeutic response for different patients, the distribution of change in radioactivity and 
volume has been shown in Figure 4.11 a and b, respectively. By this result, no correlation 
of the therapeutic response could be found in this distribution figure. 
Moreover, the patients have been divided into two subgroups aged >50 and ≤50, as 
shown in Figure 4.12 a and b, respectively. By this analysis, no significant difference could 
be found between these two subgroups, suggesting that the therapeutic response of patients 
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is not related to the age in this study. However, by further analysis on the comparison of 
the F-18 ML-10 assessment in patients aged >50 and ≤50, as shown in Figure 4.13, the F-
18 ML-10 assessment on patients elder than 50 years old shows a better linear correlation 
between tumor volume change and changes in radioactivity early after radiotherapy in this 
study (R square 0.9778 versus 0.8108). This indicates that the F-18 ML-10 early 
assessment may give a more accurate evaluation early after radiotherapy. 
 
Figure 4.11 – The change in radioactivity (a) and volume (b) from patients at different 
ages. 
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Besides, the patients have also been divided into two subgroups by gender. As shown 
in Figure 4.14, no significant difference could be found between these two subgroups, 
suggesting that the therapeutic response of patients is not related to the gender in this study. 
 
Figure 4.12 – The comparison of therapeutic response in patients aged >50 and ≤50. 
No significant difference in radioactivity change (a, p = 0. 0.5730), or subsequent 
volume change (b, p = 0.6430) was found between these two subgroups of patients.  
Moreover, as shown in Figure 4.15, the result of comparison of the F-18 ML-10 
assessment in female (blue) and male (red) patients does not show any significant 
difference in the linear correlation between tumor volume change and changes in 
radioactivity early after radiotherapy, suggesting that the applicability of F-18 ML-10 
assessment is not influenced by gender in this study. 
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Figure 4.13 – The comparison of the F-18 ML-10 assessment in patients aged >50 
(blue) and ≤50 (red). The F-18 ML-10 assessment on patients elder than 50 years old 
shows a better linear correlation between tumor volume change and changes in 
radioactivity early after radiotherapy. 
 
Figure 4.14 – The comparison of therapeutic response in female and male patients. 
No significant difference in radioactivity change (a, p = 0.3888), or subsequent volume 
change (b, p = 0.9718) was found between these two subgroups of patients. 
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Figure 4.15 – The comparison of the F-18 ML-10 assessment in female (blue) and male 
(red) patients. The F-18 ML-10 assessment on this two groups of patients does not 
show significant difference in the linear correlation between tumor volume change 
and changes in radioactivity early after radiotherapy. 
4.2.6 Discussion on the clinical application of F-18 ML-10 
Before the clinical use of F-18 ML-10 apoptosis imaging, F-18 FDG PET imaging 
has been used for the radiotherapy assessment in intracranial tumor in some studies [21, 165]. 
However, the increased F-18 FDG uptake caused by radiotherapy-related inflammation 
could lead to a false positive result in PET images. In addition, the high F-18 FDG uptake 
in normal tissue reduces the signal-to-noise ratio. Therefore, F-18 FDG imaging is not an 
ideal method for the assessment of intracranial tumor radiotherapy due to the limited 
accuracy. Lorberboym et al [28] investigated apoptosis imaging of intracranial tumor by Tc-
99m Annexin-V SPECT imaging, which could achieve better accuracy. However, it was 
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limited by the high molecular weight, slow blood clearance, immunogenicity, and poor 
specificity of Tc-99m Annexin-V [24]. 
Early quantitative assessment of radiotherapy via non-invasive imaging is important 
to evaluate the treatment and then improve clinical management. In this study, F-18 ML-
10 has been used to visualize the change of apoptosis in tumor area as an early assessment 
of CK treatment for intracranial tumor. With voxel-wise analysis as well as correlation 
analysis, the feasibility of the assessment method was demonstrated. The safety and 
efficacy of F-18 ML-10 has been investigated in preclinical studies [26] and multi-center 
clinical trials [22], suggesting good stability, safety, specificity, and rapid biodistribution. 
The concept of apoptosis was first proposed by Kerr et al [166]. A study on the 
difference between apoptotic cells and necrotic cells suggested that apoptosis is a 
programmed death process, the inhibition of which is highly related to the occurrence and 
development of tumor [167]. In addition, as B-cell lymphoma 2 (Bcl-2) gene is identified as 
a regulator of apoptosis, it is considered to be anti-apoptotic thus classified as an oncogene. 
Therefore, it is misunderstood that the apoptosis in tumor tissue is less active than normal 
tissue. In fact, more apoptosis was found in tumor tissue than normal tissue in most cases. 
In this study, a significantly higher F-18 ML-10 uptake in tumor cells was observed in 
PET/CT images. 
Cancer is treated with radiotherapy mainly by apoptosis induction [25, 29, 162]. In the 
early stage of an effective treatment, complex pathophysiological changes occur in the 
tumor, including apoptosis onset in vascular endothelial cells, vascular occlusion and 
consequent removal of necrotic cells, etc. Especially, the tumor vascular occlusion and the 
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removal of necrotic cells result in reduced tracer uptake visualized by apoptosis imaging, 
thus attenuates the overall apoptosis change in tumor tissue [9]. In this study, heterogeneous 
and two-way change of F-18 ML-10 uptake was observed in some subjects, as shown in 
Figure 4.4. Therefore, it may not be accurate to evaluate the efficacy of the treatment using 
the overall change of tracer uptake in ROI after treatment. Considering the spatial 
heterogeneity of tumor tissue, a voxel-based analysis method proposed by Moffat et al[164] 
was used in this study. The PET signal of the whole tumor tissue was divided into voxels 
– the smallest unit of three-dimensional imaging. The change in radioactivity in each voxel 
was then calculated and classified into three categories (increase, decrease, and unchanged) 
with the threshold of 12.5%. For the quantitative analysis of the voxel-wise change, the 
voxels with both increased and decreased tracer uptake (red and blue points shown in 
Figure 4.5) were put together as tissue with apoptosis change induced by radiotherapy, to 
take the heterogeneously internal changes from the tumor tissue into consideration. 
Positive correlation was observed between the change in F-18 ML-10 uptake (X) and the 
subsequent change in tumor volume (Y) with a linear regression equation: Y = 1.018 * X 
− 0.016. Additionally, the difference of voxels with increased and decreased tracer uptake 
may provide potential reference to distinguish the apoptosis and necrosis in tumor tissue. 
Twenty-nine subjects with multiple types of intracranial tumor have been investigated 
in this study, 30 lesions in 29 patients were classified into malignant and benign, according 
to 2016 WHO CNS tumors classification. A significantly different response in radioactivity, 
as well as subsequent tumor volume change, has been observed, suggesting that malignant 
tumors tend to be more sensitive to CK treatment. All 30 lesions have also been divided 
into two groups by pre-CK radioactivity, but no significant difference was found in 
 76 
radioactivity change, or subsequent volume change, indicating that the therapeutic 
response of CK treatment is not correlated with the apoptosis before CK treatment. 
Although clinical trials of small molecule probes conducted worldwide is limited, its 
potential for early assessment of radiotherapy has been proved to be effective and reliable, 
as shown in this study and previous preclinical and clinical studies [22, 23, 26]. The study is 
limited to the small samples size, and further studies are needed with large sample clinical 
data.  
4.3 Summary 
In this chapter, I demonstrate that F-18 ML-10 PET/CT apoptosis imaging to be a safe 
and effective clinical method for the assessment of early response of radiotherapy. In F-18 
ML-10 PET/CT apoptosis imaging, the tracer uptake in normal brain tissue is lower than 
that in tumor tissue, thus the anatomic positioning of tumor tissue and surrounding edema 
area could be accurately identified and visualized. More importantly, F-18 ML-10 PET/CT 
apoptosis imaging can be used for early prediction of the effectiveness of CK radiotherapy. 
A significant correlation between the rate of change in F-18 ML-10 uptake in the tumor 
and the rate of subsequent change in tumor volume was observed. In comparison to the 
therapeutic response in different cancer types, a rapid response in radioactivity, as well as 
subsequent tumor volume change, has been observed in malignant tumors, which tends to 
be more sensitive to CK treatment. Another comparison indicates that the therapeutic 
response of CK treatment is not significantly correlated with the apoptosis level before CK 
treatment by the study. By analyses on the application of this method on different patients, 
the result indicates that the F-18 ML-10 early assessment may give a more accurate 
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evaluation early after radiotherapy. Our study has also shown the accuracy of AMIC Ray-
Scan 64 PET/CT and safety of CK stereotactic radiosurgery treatment of intracranial 
tumors in PLAGH. 
4.4 Experimental 
4.4.1 Subjects 
From January 2014 to December 2015, 29 human subjects (30 lesions) with 
intracranial tumors in our institution scheduled to undergo CK stereotactic radiotherapy, 
were enrolled in the study. These patients were strictly selected according to the integration 
and elimination standards and their informed consents have been acquired. 
The inclusion criteria were as follows: 1, the patient voluntarily subjects to this study, 
and the patient or legal representative signs the informed consents; 2, the patient is between 
18 to 75 years old; 3, the patient has been diagnosed as intracranial tumor and meets the 
criteria for CK treatment; 4, there are no abnormal findings on patient’ routine blood, urine, 
and biochemical examination, electrocardiogram (ECG) and chest X-ray.  
4.4.2 Informed consent and statement of human rights 
Informed consent was obtained from all participants. All protocol of this clinical study 
has been approved by Institutional Review Board of Chinese PLA General Hospital 
4.4.3 Imaging protocol 
4.4.3.1 PET/CT acquisition protocol 
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PET/CT imaging were performed before and 48 hours after CK therapy with AMIC 
Ray-Scan 64 PET/CT system (AMIC, Beijing, China), 90 minutes after F-18 ML-10 tracer 
injection with 0.12 mCi/kg b. w. The F-18 ML-10 tracer was produced at the Department 
of Nuclear Medicine at PLAGH PET Facility[163] with PET-MF-2V-IT-I Fluorine 
multifunctional synthesis module (PETKJ, Beijing, China), and the radiochemical purity 
is of >98% by HPLC. 
PET images were acquired by three-dimensional brain mode, with 2.5-mm slice width, 
512 × 512 reconstruction matrix. CT images were acquired with a 50-cm field of view 
(FOV), 75-cm diameter of gantry, 2.5-mm of slice width, 150-cm maximum positioning 
length, 175-cm axial moving range of patient bed, and 512 × 512 of reconstruction matrix. 
4.4.3.2 MRI acquisition protocol 
MRI and CT scanning were used for location of tumor and anatomic assessment of 
the tumor response 2 to 4 months after radiotherapy. All MRI images were acquired on the 
1.5 Tesla (1.5 T) MRI scanner (Siemens Espree, Siemen, Erlangen, Germany). Axial T1- 
weighted imaging (T1WI) was acquired, with slice width of 0.7 mm, repetition time (TR) 
= 1650，echo time (TE) = 3 ms; T2- weighted imaging (T2WI) was acquired, with slice 
width of 1.0 mm, TR = 5500, TE = 93 ms. 0.2 mmol/kg b.w. of Gadolinium-
diethylenetriamine pentaacetic acid (Gd-DTPA) was injected intravenously prior to 3D 
T1WI enhanced imaging with above parameters. 
4.4.3.3 CT acquisition protocol 
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CT images for localization of tumor were acquired on Brilliance TM (Philips 
healthcare, Amsterdam, Netherland), with an 80-cm maximum field of view (FOV), 60-
cm actual FOV, 85-cm diameter of gantry, 1.5-mm of slice thickness, 150-cm maximum 
positioning length, 190-cm axial range of patient bed, and 1024 × 1024 of maximum 
reconstruction matrix. 
4.4.4 Radiotherapy protocol 
CyberKnife which enables stereotactic radiosurgery delivery applied in this study was 
manufactured by Accuray (Accuray Inc., Sunnyvale, CA, USA). Non-isocentric treatment 
plan was implemented through accelerator mounted on the robotic arm with continuous 
real-time image-guided technology. 
The blood, urine as well as biochemical examination, ECG and chest X-ray was 
acquired before. After enrolment, patients underwent head CT and MRI scanning for 
location of tumor. For each patient, the acquired CT images was co-registered with MRI 
images by MIM software (version number: 6.5.4), which was imported into CyberKnife 
Robotic Radiosurgery System (Multiplan 4.0.2) for target and organs at risk delineation. 
With the information provided by the fused images, the target area of CK treatment was 
optimized and the gross tumor volume (GTV) was recorded by radiologists and physicians. 
Patients underwent CK stereotactic radiosurgery with 6D⁃skull tracking, and the treatment 
scheme was with 14-24 Gy in 1-3 fractions depending on the tumor size and position.  
4.4.5 Imaging analysis 
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Voxel-based analysis on PET/CT image was used in the apoptosis imaging visual 
analysis, which performs voxel-by-voxel subtraction of the change PET/CT before (pre-
CK) and early after CK treatment (post-CK). The PET/CT data of pre-CK and post-CK, 
along with CT, MRI and GTV data, were delivered to the MIM image processing software 
after acquisition. The CT data with GTV information were registered with data from 
PET/CT imaging. With the imported GTV information as reference, region of interest (ROI) 
was plotted in MIM software. Each voxel value in PET / CT images was represented by 
radioactivity (Bq/ml) or standardized uptake value (SUV). The images of MRI, CT and 
PET/CT were registered and the voxel size and slice width from different imaging 
modalities were normalized. The values of radioactivity for each voxel in the ROI were 
collected separately on baseline PET scan and the follow-up. The percentage change in 
each voxel was calculated. Voxel-based subtraction PET images were acquired using MIM 
software for visual analysis to observe the changes of cell apoptosis before and after CK 
treatment. 
4.4.6 Statistical analysis 
For statistical analysis, two-tail paired Student’s t-tests were applied with SPSS 19.0 
to analyze the change in radioactivity before and after treatment. Correlation between 
change ratio of radioactivity and lesion volume was analyzed with linear regression 
analysis. And p < 0.05 was considered as statistically significant. 
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CHAPTER 5. OTHER RELATED WORKS 
In previous chapters, I demonstrated how molecular imaging meets the clinical needs 
for early assessment by F-18 ML-10 apoptosis imaging. Furthermore, molecular imaging 
could also play important role in early diagnosis and intraoperative tumor detection by 
distinguishing cancer tissue from normal or other tissues. In this chapter, I demonstrate the 
analysis of the sensitivity of three molecular probes for hand-held spectroscopic device. 
The fluorescence and Raman spectroscopy has been normalized and then analyzed. The 
surface enhanced Raman scattering (SERS) gold nanoparticles have been proved to be 
ultra-high sensitive for in vitro detection, with wide dynamic range, thus could achieve 
distinguishing of signal of tumor tissue from that of normal tissue. Furthermore, the 
differentiation of tumor tissue from inflammatory tissue has also been investigated by a 
preclinical quad-modality imaging with applying multiple probes. 
5.1 Sensitivity of hand-held spectroscopic imaging for surgery guidance 
5.1.1 Introduction 
As discussed in previous chapters, the use of novel F-18 pharmaceuticals for 
assessment of cancer therapy has been investigated by distinguishing of the apoptotic cells 
from viable cells. Such early assessment provides opportunity to early management of 
cancer therapeutics. Furthermore, it is also important to distinguish the subtle metastases 
while surgery operation. In this chapter, I further demonstrate the sensitivity of novel 
molecular probe in real-time guidance for cancer surgery. 
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Dr. Shuming Nie and colleagues from our group in Emory University first developed 
spectroscopic device configured with handheld laser probes, and showed that the device 
has a high detection sensitivity for ICG, can effectively distinguish and label the tumor 
tissue/lymph and the normal tissue [82]. With this spectroscopic device, the SERS signal 
could be detected as well. Molecular probes based on nanoparticles that produce signal 
from SERS have been investigated widely [168-178]. Research and clinical trials for the 
device has been conducted in the Emory University Hospital and the Affiliated Hospital of 
Pennsylvania, for imaging-guided breast, lung, colon and pancreatic cancer surgery. About 
200 cases of surgical results have supported the effectiveness of the device [81, 83, 179]. The 
advantages of this device are shown as following: 
(1) Ultra high detection sensitivity that can achieve single cell detection level at 
laboratory and is able to observe subtle metastases while surgery operation, superior to 
similar devices either domestic or abroad. 
(2) No requirement for the in-situ injection of ICG, thus largely reduces the background 
noise, and helps to exactly locate the tumor before surgery and judge whether there is 
residual cut edge after the surgery. 
(3) Direct detection and real-time observation of tumors while surgery operation. 
(4) Applicable for multiple types of cancer. 
(5) High speed imaging and data processing system, enabling the real-time observation 
during surgery operation. 
5.1.2 Results and discussion 
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5.1.2.1 Detection system and photo-stability analysis of three molecular probes 
As introduced previously, the SpectroPen could allow sensitive detection by 
collecting characteristic emission from reagents those who are excited by a laser. The laser 
utilized by the SpectroPen spreads in a form of the Gaussian beam, so the excitation 
intensity would be different with the change of distance between the Pen and the sample 
solutions. The maximal intensity of the laser could be reached when the sample would be 
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The radius of the laser spot is theoretically 1 cm, so that the highest energy of the laser 
beam should be around the area of 1 cm away from the sampling head. With the higher 
excitation, more electrons in reagent solutions would be excited, resulting in a higher 
intensity of the emission signal received via the SpectroPen. 
As shown in Figure 5.1, distance dependence was investigated by an experiment of 
varying the distance between the Pen and the samples. The reagent for this distance 
dependence experiment is SERS-tag nanoparticles with the concentration of 50 pM. All 
the signals collected by detector under certain distance have been integrated to indicate the 
total intensity of the emission, which is proportional to the excitation energy. As depicted 
in Figure 5.2a, the detector could receive the highest signal intensity when the sampling 
head is located at 8 mm away from the top of the sample solution. 
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5.1.2.2 Limits of measurement comparison among QD, IR dye and SERS gold 
nanoparticle 
 
Figure 5.1 – Setup for detection system (a) and for the distance dependence (b). 
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Figure 5.2 – (a) The signal from SERS-tag nanoparticles at concentration of 50 pM 
collected by detector at detection distances ranging from 4 mm to 40 mm. (b) 
Photostability test of 5 nM of Qdot 800 (blue line), 5 nM of IRDye (cyan line), 0.75 
pM of SERS-tag nanoparticles (red line), and background (black line). 
To investigate whether the SERS-tag nanoparticles remain photosensitive when 
shined under the focused laser beam, we studied the photobleaching of SERS-tag 
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nanoparticles and compared with IRDye 800 and Qdot 800. As shown in Figure 5.2b, the 
results suggest that there was no noticeable photobleaching for the nanoparticles over the 
average detection period for SpectroPen, while decreases in fluorescence intensity were 
observed for other two reagents with the same setup. The signal of Qdot 800 decreases 30% 
of the original fluorescence intensity within the first 0.3 second excitation, but the emission 
intensity remains 61.8% after 2.8 second shining under laser. The reagent IRDye 800, 
however, suffers from the severe photobleaching – there is only 21.8% remaining intensity 
after the reagent exploded under laser for 2.8 second. 
As shown in Figure 5.3a, the original spectra of three reagents were detected by 
SpectroPen with considerable signal-to-noise ratio. In the SERS spectrum, the 
wavenumber was converted to wavelength prior to comparing the limit of measurement. 
In this study, the limit of measurement has also been determined as the minimal 
spectrally resolvable concentration. As depicted in Figure 5.3b, taking the quantum dots 
(QD) 800 as an example, as the spectrum of 0.025 nM QD 800 is the minimal spectrally 
resolvable concentration, this would be considered as the limit of measurement of QD 800 
by this SpectroPen. To better analyze the linearity and dynamic range of fluorescent signal, 
all the data point in the same range of wavelength (i.e., 797.52 – 931.20 nm, or 200 – 2000 
cm-1) has been integrated.  
As the analysis of SERS spectrum usually based on the “fingerprint” in the spectrum, 
rather than the overall integration, the method of integration for SERS signal has been 
compared as shown in Figure 5.4. As shown in Figure 5.4a, we integrated all the data from 
200 – 2000 cm-1 without any further data processing. The R square value is 0.99847. 
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However, for SERS signal, there is a high background caused by the SERS signal itself. 
Therefore, partially integration of the data after subtracting the baseline has been analyzed, 
where the baseline was defined as the lowest value of the data in the range from 400 to 
1700 reciprocal centimeter. The R square value is slightly higher, which is 0.99862. 
 
Figure 5.3 – (a) Original spectra of QD, IRDye, and SERS gold nanoparticles detected 
by SpectroPen; (b) determination of limit of measurement with different 
concentration of QD solution. 
As the peak at 1507 cm-1 is one of the characteristic peaks of this SERS agents, the 
peak height has also been used for the analysis. The linearity of the last method is the best 
of all three methods, where the R square value is 0.99915. The last analytical method 
provides the most accurate relationship between signal weakness and concentration of 
SERS agents. Therefore, we use this peak height method to analyze the SERS signal. 
However, for the comparison of three reagents, the integrated method is adopted to keep 
the comparison consistent. 
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Figure 5.4 – Integration of SERS signal: (a) integration of data from 200 – 2000 cm-1; 
(b) partial integration of data after subtracting the baseline from solvent; (c) the 
intensity of one characteristic peak at 1507 cm-1 after subtraction of baseline. 
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In this study, the reagents were firstly diluted in water. However, the signal, especially 
for low concentration, are various under the same condition, due to adhesion of the particles 
to the surface of tubes. As the bovine serum albumin (BSA) is usually be supplied to 
prevent this adhesion. Therefore, we applied 1% BSA in the solvent to prevent reagents 
absorbing to the wall of wells. Diluted in BSA solution, the reagent provides a more stable 
signal at low concentration, and the comparison of BSA solution and aqueous solution is 
shown in Figure 5.5. 
 
Figure 5.5 – Comparison of solvent: 1% BSA solution (red) and aqueous solution 
(blue). 
To measure the limits of detection of IRDye 800, the solution was diluted to 
concentrations ranging from 0.01 to 0.5 nM. The spectra are shown in Figure 5.6a, the 
minimal spectrally resolvable concentration of SERS agent is 5×10-11 M (i.e., 0.05 nM), 
with the detection distance of one centimeter. 
The Quantum dots were also diluted to concentrations ranging from 0.01 to 0.5 nM. 
The minimal spectrally resolvable concentration of Quantum dots is 2.5×10-11 M (i.e., 25 
pM), under one-centimeter detection. To measure the limits of detection of SERS 
nanoparticles, the solution was diluted to concentrations ranging from 0.1 pM to 5 fM. 
According to the peak height analytical method, the spectra after subtracting background 
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is shown in the Figure 5.6c. As depicted in this figure, the minimal spectrally resolvable 
concentration of SERS agent is 5×10-11 M (i.e., 5 fM), under one-centimeter detection. 
 
Figure 5.6 – Limit of measurement of IRDye 800 (a), Qdot 800 (b), and SERS gold 
nanoparticles (c). 
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By further investigation on the limit of measurement of SERS gold nanoparticles, the 
detection under 8 mm for as long as 30 second integration has been set. As shown in Figure 
5.7, the result suggests that the spectrum of 1 fM SERS agents cannot be detected. But the 
signal-to-noise ratio at concentrations of 10 fM, 5 fM, and 2.5 fM is acceptable. So that the 
SERS particles have an ultra-sensitivity, that is, 2.5×10-15 M, for SpectroPen detection. 
 
Figure 5.7 – Limit of measurement of SERS gold nanoparticles with 30 second 
acquisition under focus distance. 
As the laser of SpectroPen spreads like a Gaussian beam, the depth of focus is defined 
by the radius of the laser spot, which could be calculated to 1 cm. The beam could be 
treated as a cylinder shown in Figure 5.8a. The exact volume of solution under laser shining 

















It is suggested that the minimum of the gold nanoparticles number for SpectroPen 
detection is around 95 particles. 
 
Figure 5.8 – Schematic of Gaussian beam (a) and the laser beam travel through the 
detection system (b). 
5.1.2.3 Dynamic range of detection of three molecular probes by SpectroPen 
To investigate the dynamic range of the detection, the molecular probes have been 
diluted into a wide range of concentration. As those fluorescent agents cannot tolerate a 
long integration time, owing to the photo bleaching, the one second acquisition was taken 
for the normalization. As SERS particles are photo-stable, they can be used to acquire 
signal with longer time. Therefore, the acquisition time for IR800 and QD800 were limited 
to no longer than one second, while for SERS particles, the acquisition time could be longer 
than 10 second. 
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Figure 5.9 – Dynamic range of IRDye 800 (a), Qdot 800 (b), and SERS gold 
nanoparticles (c). 
As shown in Figure 5.9, the dynamic range of IRDye 800 (a), Qdot 800 (b), and SERS 
gold nanoparticles (c) are 1, 1, and 4 orders of magnitude, respectively. With a much wider 
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dynamic range, SERS particles could have great potential to accurately discover tumor-
margin, where the signal would be much lower than central tumor tissue. Although the 
SERS signal saturates the detector of SpectroPen at the concentration of 75 pM, the signal 
intensity could reach a high level with the increase of the concentration to nM level. 
Therefore, for the same concentration of reagents, SERS particles would have an 
overwhelming high intensity of signal, resulting in a potentially more accurate but less 
expensive diagnostic approach. On the other hand, focused on the application of 
SpectroPen, SERS particles could provide a considerable high signal at a low concentration, 
which would help with reducing the toxicity and side effect of the agent itself. Thanks to 
its ultimate photo stability, SERS particles may have potential to achieve a higher 
sensitivity with intense stimulation. 
5.1.3 Summary 
In this chapter, I demonstrate the sensitivity investigation of widely used optical 
probes for SpectroPen real-time guidance for tumor removal surgery. The limit of 
measurement of SERS particles is 10 thousand times lower than QD800, even 20 thousand 
times lower than IR800. Furthermore, the dynamic range of SERS nanoparticles is more 
than 300-fold higher than other 2 imaging probes. 
These parameters are important for the application of SpectroPen. The Limits of 
Detection, on one hand, determines the minimal quantity of the injection of contrast agents, 
which could help with reducing side effect and toxicity. On the other hand, weak tumor-
margin signals that are 50-60-fold lower than the central tumor signals. The wider dynamic 
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range provides opportunity for simultaneous measurement without adjusting the data 
acquisition parameters. 
5.1.4 Experimental 
5.1.4.1 Detection sensitivity and dynamic range measurement: 
The reagents were diluted in 1% BSA in Phosphate buffered saline (PBS) solution, as 
well as in water, to a concentration of 5.0 × 10-15 – 1.0 × 10-8 M for SpectroPen detection. 
300 μL of these reagent solutions and pure solvents for control were transferred into 
different wells in a 96 well cell culture plates (polystyrene). As previously described, the 
SpectroPen [82] combines a pen-shaped sampling head and a Raman spectrometer via a FC 
connector, with a Raman shift range of 200 – 2000 cm-1. Emitting at 785 nm, the excitation 
is provided by 200 mW near infrared diode laser. The setup of SpectroPen is shown in 
Figure 5.10a and Figure 5.10b. The sampling head was fixed above the center of each well 
of the plate. The distance between detector and the sample was measured by a ruler. The 
integration time of collection was selected properly from 0.1 to 10 s. 
5.1.4.2 Tissue penetration measurement 
To determine the penetration depth of the SpectroPen detection, chicken breast tissues 
were utilized to mimicry the human tissue. As shown in Figure 5.10c and Figure 5.10d, 
droplets of SERS-tag nanoparticles with different concentration and different volume were 
held by (under) a Parafilm. On the top of the film, different thickness of the meat was put 
between SERS-tag nanoparticles sample and the SpectroPen. The fluorescence or Raman 
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spectra were collected from 0.05 to 30 s, depending on the signal-to-noise ratio of the 
spectra. These tissues were cut to the thickness ranging from 1 to 10 mm, step by 1 mm. 
 
Figure 5.10 – Experimental setup. (a) Sketch and (b) photograph for SpectroPen 
detection of IR dye, Quantum Dots, and SERS-tag nanoparticles in a 96-well plate. (c) 
Sketch and (d) photograph for tissue penetration depth studies. 
5.2 Preclinical Application on a small animal quad-modality imaging system to 
distinguish tumor tissue and inflammatory tissue 
5.2.1 Introduction 
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Molecular imaging plays a key role in biomedical research. Recent developments in 
both imaging techniques and novel molecular probes have sparked great desires for the 
development of multi-modality and multi-probes molecular imaging instruments.  
Up to now, three major molecular imaging modalities have been mostly used, which 
are PET, SPECT, and fluorescence imaging. Positron emission tomography (PET) and 
single photon emission computed tomography (SPECT) rely on radiolabeling, which are 
already clinically used as powerful imaging techniques. Fluorescence imaging relies on 
optical labeling, such as Green fluorescence protein (GFP), which is favored by researchers 
due to its versatility and ease of make and use. Several articles have discussed the feasibility 
and potential opportunities of combining the PET-SPECT and radiology-optical imaging 
modalities, and recommended to use these kinds of strategies in biomedical research. As a 
quad-modality molecular imaging system has been developed by our group, the biomedical 
application could be investigated by using this device 
5.2.2 Results and discussion 
5.2.2.1 Phantom imaging study 
We first investigated the imaging and co-registered performance by using a custom-
made multi-modality imaging phantom. The phantom is a solid cylinder having a light 
scattering property similar to tissue (Figure 5.11p). There are two holes in this cylinder 
where glass tubes with radiolabeling medicines and fluorescence dyes can be inserted, as 
shown in Figure 5.11q. With a designed imaging protocol, multimodal molecular imaging 
of this phantom was performed in a sequential mode. Figure 5.11 shows the imaging results, 
including images not only by different modalities but also from the co-registered fusion. 
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Both PET and SPECT provided high quality images without crosstalk. We intended to 
make a small bubble separating two PET medicine drops, and this small gap was clearly 
distinguished in PET images with high spatial resolution. In addition, FMI also 
successfully reconstructed the fluorophores deep in the phantom. In Figure 5.11r, the 
maximum intensity projection (MIP) rending of the fusion images demonstrated the co-
registration performance.  
5.2.2.2 Small animal imaging study 
We induced a xenograft tumor and an inflammation in the right shoulder and the right 
hind limb of a BALB/C nude mouse, respectively. We used F-18 FDG for PET imaging, 
Tc-99m 3PRG2 for SPECT imaging and Cy7-entrapped CCPM nanoparticles for 
fluorescence imaging. F-18 FDG, which is taken by high-glucose-using cells, has been 
widely used for PET imaging of tissue metabolism; Tc-99m 3PRGD2, which is a Tc-99m 
labeled dimeric cyclic RGD peptide with increased receptor binding affinity and improved 
kinetics for SPECT imaging, is able to target integrin αvβ3-positive tumors; and Cy7-
entrapped CCPM nanoparticles, which is a near-infrared (NIR) fluorescence (NIRF) 
imaging tracer for optical imaging, can preferentially accumulate in tumor site because of 
the enhanced permeability and retention (EPR) effect, which is characterized by 
microvascular hyperpermeability to circulating colloidal particles and impaired lymphatic 
drainage in tumor tissues. 
Figure 5.12 shows multi-modality and multi-probe imaging results. Complementing 
the CT scanning results, the PET images showed high radioactivity accumulation in the 
brain, the right shoulder and the right legs (Figure 5.12e). In SPECT images, the 
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radioactivity accumulation of Tc-99m 3PRGD2 primarily occurred in the right shoulder, 
the abdomen, and the area of bladder (Figure 5.12h and Figure 5.12i). Besides, according 
to the FMI imaging results in Figure 5.12m, only the area of right shoulder had a significant 
accumulation of Cy7-entrapped CCPM nanoparticles.  
 
Figure 5.11 – The imaging results of the multi-modality phantom. The CT images (a-
b), PET images (d-f), SPECT images (g-i), FMI images (j-l) and quad-modality fusion 
images (m-o) are presented. In the results, the quality of SPECT images has not been 
affected by the crosstalk from the positron-emitting radionuclides. The MIP rending 
of the fusion images (r) demonstrated the co-registration performance. The imaging 
results indicate that our hybrid multi-modality imaging system resulted in 
appropriate imaging and accurately co-registered performances. The right, middle 
and left color bar correspond to the PET images, the SPECT and FMI images 
respectively. Reprinted from Lu et al [78] with permission. Copyright © 2014 Society 
of Nuclear Medicine and Molecular Imaging, Inc. 
From either the PET image or SPECT image alone, the tumor area remained unclear. 
However, we were able to identify the tumor’s location by the complementary information 
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obtained from the PET-SPECT-CT fusion images (Figure 5.12k). On the other hand, FMI 
image gave the right suspicious area, but the imaging resolution is low. Complementing 
FMI with radioactive molecular imaging significantly improved both specificity and 
resolution. This result successfully demonstrated the superior power of multimodal 
molecular imaging. 
 
Figure 5.12 – Quad-modality in vivo animal study. Complementing the CT scanning 
results (a-c), the PET images (d-f) showed high radioactivity accumulation in the 
brain, the right shoulder and both legs. In SPECT images (g-i), the radioactivity 
accumulation of 99mTc-3PRGD2 in the right shoulder, the abdomen and the area of 
bladder was evident. There was only the area of right shoulder that had a great 
accumulation of Cy7-entrapped CCPM nanoparticles (m). (n) shows the white light 
image provided by FMI modality. We were able to identify the tumor’s location by 
the complementary information obtained from the PET-SPECT-CT fusion images (j-
l), and in addition the FMI imaging result has also confirmed it. The histology (o) 
confirms the tumor area of right shoulder with high cell proliferation observed with 
high tracer uptake in PET, SPECT and FMI images. The histology (p) confirms the 
inflammation area of right leg with a large number of inflammatory cells such as 
neutrophils (arrow) showed increased F-18 FDG accumulation in PET images. The 
right, middle and left color bar correspond to the PET images, the SPECT and FMI 
images respectively. Reprinted from Lu et al [78] with permission. Copyright © 2014 
Society of Nuclear Medicine and Molecular Imaging, Inc. 
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Moreover, by following optimized imaging procedure, the entire imaging time for this 
in vivo study, including preparation and imaging, took only 3 hours. However, it can be 
over 6 hours by simply summation of all imaging times from each individual modality. 
The significant reduction in imaging time is essential to study dynamic physiologies. 
In animal disease model study, the quad-modality imaging system successfully 
acquired tumor images non-invasively and in vivo. The animal experiment validated that 
the four modalities of PET, SPECT, FMI and CT can provide more comprehensive 
information for molecular imaging studies, improving the overall specificity. In our study, 
the fusion images of a tumor-xenograft mouse (Figure 5.12) showed complementary 
information that differentiated between the tumor location and the inflammation location. 
These findings were confirmed by ex vivo histology. 
Comparing to the great potential applications of the quad-modality imaging protocol, 
the tumor imaging result, which we presented previously, is only a drop of the bucket. 
Metabolism, metastasis and neovascularization are most three important characteristics of 
the biologic behavior of cancer cell. Differentiation of the subtypes of the same type of 
cancer cell can result in different biological behaviors and variations in the biologic 
behavior of cancel cell cause different responses to the treatment. Traditionally, molecular 
biology approaches such as immunohistochemistry are used for revealing the biologic 
behavior of cancer cells, however recently molecular imaging approaches, which allows 
for noninvasive in vivo imaging and quantification of biologic processes such as 
metabolism, metastasis and neovascularization, are more and more widely used in these 
studies. For instance, the GFP gene can be introduced into cancer cells for monitoring the 
metastasis of the cancer by using FMI, the F-18 FDG can be adequate in precisely 
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quantifying the metabolism of cancer cells through PET imaging and the Tc-99m 3PRGD2 
can reveal the neovascularization of the cancer cells by SPECT imaging. It should be noted 
that the complexity of biologic behavior of cancer cells is beyond the ability of any single 
molecular imaging approaches, or molecular tracer, to reveal. Thus, multi-modality and 
multi-probes molecular imaging would be great helpful in better observing and predicting 
the biologic behavior of cancer cells. Considering this, we developed the quad-modality 
molecular imaging system which includes the three major molecular imaging modalities 
of PET, SPECT and FMI, as well as an X-ray CT to provide the anatomical information. 
Multimodal molecular imaging generally required an extended time. For instance, in 
our system, SPECT typically needs to wait for 60 minutes after the injection of medicine, 
and it took another 20~30 minutes to finish the scanning. In addition, different imaging 
modalities might have conflicts, such as the potential risk of crosslink between PET and 
SPECT. However, summation of operation time by all three molecular imaging modalities, 
as well as the waiting time of short-lifetime radioactive medicine, will be about 6 hours. 
Thus, the procedure of multimodal molecular imaging must be carefully optimized to 
minimize the total scanning time. To avoid crosslink, the PET tracer was injected after the 
SPECT scan in our system. In addition, long lasting fluorescence tracers could be injected 
the day before the experiment. Finally, we achieved a 3-hour imaging time. The total length 
of the scanning time can be even shortened by performance improvement of the imaging 
system. For example, we can inject both radiolabeling tracers simultaneously by using a 
better SPECT detector which can differentiate signals from PET tracer [63]. 
5.2.3 Summary 
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In this chapter, I have demonstrated the classification of tumor tissue from 
inflammatory tissues by a quad-modality molecular imaging system with application of 
three different molecular probes in an animal model. F-18 FDG traces the abnormal 
metabolic activities by PET imaging. However, the tumor site and inflammation tissue both 
have high metabolism, thus could not be distinguished by PET in this disease model. Tc-
99m 3PRGD2 reveals the neovascularization of the cancer cells by SPECT imaging, and 
Cy7-entrapped CCPM nanoparticles preferentially accumulate in tumor site because of the 
EPR effect. From either the PET image or SPECT image alone, the tumor area remained 
unclear. With the comprehensive information collected from four modalities, the tumor 
tissue has been successfully distinguished from other false-positive signal from 
inflammation. Therefore, it is suggested that the tumor tissue could be distinguished in vivo 
by appropriate application of multimodality molecular imaging along with multiple 
molecular probes. In current stage, many molecular probes are only available for 
preclinical uses, which may limit the clinical application of multimodality imaging. With 
the development of more safe and efficacious molecular probes, the molecular imaging 
will be a powerful weapon for the classification and distinguish of tumor for early diagnosis. 
5.2.4 Experimental 
5.2.4.1 Multi-modality imaging protocol 
A phantom and a mouse were scanned to evaluate the imaging capability and fusion 
performance of the system. Geometric calibration and image co-registration was processed. 
Because the FMI module was setup opposite to the PET/SPECT/CT modules, we generally 
started with FMI imaging when performing multi-modality imaging, then rotated the 
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animal bed in the direction of the PET/SPECT/CT modules for the remaining imaging 
procedures. 
Both phantom and animal experiments were carried out to evaluate the imaging 
capability and fusion performance of the system. As discussed, vast differences in uptake 
period and imaging technique, each molecular imaging modality requires specific 
procedure. Therefore, the overall imaging time can last six hours in our system without 
optimization of the imaging protocols. However, long imaging time not only brings 
difficulties in dynamic study, but also may cause health hazard for animals. Thus, 
optimization in the imaging protocol for multimodal molecular imaging is in great desire. 
Given a physiological or pathological study case, several primary issues to be considered 
in assigning the imaging sequence are: 
1) Uptake time; 
2) Preferred imaging period after uptake; 
3) Imaging operation time; and 
4) Potential crosstalk with other modalities. 
In this chapter, the overall optimization principle is: performing imaging with short 
uptake during the long-uptake period of other modalities; putting modalities that can cause 
crosstalk with others after its conflict counterparts. 
Figure 5.13a listed both imaging period and the uptake period of three molecular 
tracers. Among them, the radionuclides used in PET imaging will cause a serious crosstalk 
 105 
problem on the quality of the SPECT imaging (Figure 5.14), the imaging time will be much 
longer if we start with PET imaging before SPECT imaging. In addition, due to relative 
long-uptake period for FMI, other modalities can be performed earlier than FMI. Based on 
these considerations, Figure 5.13b presented our optimized imaging protocol. The total 
imaging time was shortened to be 180 minutes without the crosstalk influence. 
 
Figure 5.13 – Timeline schematic of the whole animal experimental procedure. A 
typical multi-modality scanning procedure in animal studies takes about 270 minutes, 
considering the time needed for drug metabolism. Adapted from Lu et al [78] with 
permission. Copyright © 2014 Society of Nuclear Medicine and Molecular Imaging, 
Inc. 
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5.2.4.2 Phantom studies 
The phantom was a cylinder (30 mm in diameter 57 mm long) made of polyvinyl 
chloride resin, which had a similar light scattering property to that of animal tissue.  
 
Figure 5.14 – Scattering influence on the quality of the SPECT imaging, which is 
caused by the crosstalk from the positron-emitting radionuclides. (a) Without the 
crosstalk of positron-emitting radionuclides, the SPECT module had a good imaging 
performance. (b) The imaging performance was degraded with the crosstalk of 
positron-emitting radionuclides. 
The phantom contained two glass tubes (inner diameter: 2.2 mm, length: 50 mm) at 
different insertion depths (28 mm and 45 mm). The bottom zones of the glass tubes were 
injected with 20 μL (10 μM) indocyanine green (ICG) as the fluorophore for FMI; the 
middle section of the 45-mm-insertion-depth glass tube was injected with 7.4 MBq (0.2 
mCi) of Tc-99m 2-Methoxyisobutylisonitrile (Tc-99m MIBI). The phantom was placed on 
the animal bed, which was located within the field of view for the FMI module, and 
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performed fluorescence molecular tomography scanning (360º rotation, scanned for 4 s / 
10º, 36 angles in total), after which the animal bed was shifted to the field of view for the 
PET/SPECT/CT modules and subject to SPECT scan (180º rotation, scanned for 10 s / 3º, 
60 angles in total). After completion of the SPECT scan, the middle section of the 28-mm-
insertion-depth glass tube was injected with 7.4 MBq (0.2 mCi) of 2-deoxy-2-(18F)fluoro-
D-glucose (F-18 FDG) for the PET scan (300 – 650 keV energy window and 12-ns timing 
window, scanned for 5 min / per bed positions, 3 bed positions). Finally, the phantom was 
moved to the field of view for the helical CT scan (60 slices, 1.32 mm helical pitch, 360 
projection numbers and 25 ms sampling intervals; X-ray tube voltage = 50 keV, at 10 mA).  
5.2.4.3 In vivo animal studies 
We performed studies on a 16-weeks old, 20-g BALB/C male nude mouse bearing a 
10 mm2 xenograft tumor [induced by hypodermic injection of human pulmonary 
adenocarcinoma A549 cells (2.5  107, 2.5 mL) were injected subcutaneously into the right 
shoulder flank area of ~16-week-old male nude mice (BALB/c, nu/nu)] in its right shoulder, 
and chronic inflammation [induced by injecting a proinflammatory substance of Bacillus 
Calmette-Gu (1 mg/ml, 0.2 mL respectively) into subcutaneous air pouches produced on 
right hind limb flank area of the mouse] in its right hind limb. The mouse was intravenously 
injected with 0.2 ml (1.51015 particles/mouse) Cy7-entrapped CCPM nanoparticles and 
37.0 MBq (1.0 mCi) 99mTc-3PRG2 via the tail vein. After 50-min uptake period, the 
mouse was subject to the anesthesia procedures [2.50% isoflurane in oxygen (1.5 L/min) 
for inducing anesthesia then lower to 1.00% isoflurane in oxygen (0.8 L/ml) for 
maintenance], to prevent motion during the multi-modality scanning. The mouse was 
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scanned with SPECT (180º of rotation, 20 s / 3º, 60 angles; duration 20 min) after the 60-
min uptake period of Tc-99m 3PRGD2. Then the mouse was intravenously injected with 
37.0 MBq (1.0 mCi) F-18 FDG via the tail vein and the anesthesia gas increased to 2.5% 
isoflurane in oxygen during the injection and lower to 1.00% after the injection. In the end 
of the 120-min uptake period of Cy7-CCPM nanoparticles, a helical CT scan (scanned for 
60 slices, 1.5 mm helical pitch, 360 projection numbers and 25 ms sampling intervals, X-
ray tube voltage is 50 keV and the tube current is 10 mA) was performed to the mouse to 
obtain CT images. The FMI scan (reflection scan mode for the whole body, integration 
times of 5s) was started after positioning the mouse on the animal bed. After a 60-min 
uptake period of F-18 FDG, the mouse was PET scanned (300 - 650 keV energy window, 
12-ns timing window, 10 min / bed position) for 40 minutes of four bed positions. The 
whole animal experimental procedure is illustrated in Figure 5.13b. After the examination, 
the mouse was sacrificed and the tumor and inflammation tissues were excised, fixed in 4% 
paraformaldehyde and embedded in paraffin. Hematoxylin-Eosin staining was performed 
on 5-μm-thick tissue sections. 
The PET/SPECT/CT images were reconstructed as aforementioned. Since the 
subcutaneous tumor lied in a very shallow region of the body, only the 2D fluorescence 
imaging were given using the epi-illumination FMI. All the reconstructed images were co-
registered automatically to perform image fusion. Animal studies were performed in 
accordance with the guidelines from the Peking University Laboratory Animal Centre and 
protocols approved by this institution. 
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CHAPTER 6. CONCLUSION AND OUTLOOK 
In this dissertation, I start the investigation on quality control of the synthesis of F-18 
ML-10 by elucidating the effect of reductive stabilizer and pH value on the false negative 
results K2.2.2 detection. After this part, I demonstrate F-18 ML-10 assessment of 
radiotherapy as a clinical method for the early evaluation of tumor radiotherapy, and the 
applicability of this method has been discussed by different brain tumor types. Besides, it 
is suggested that this method shows the potential for the future assessment of subsidiary-
injury of lung cancer radiotherapy by clinical and animal studies. 
In chapter 1, I introduce the background and priniciples of the researches in this 
dissertation. 
In chapter 2, I demonstrate that the interference from reagents commonly used in F-
18 pharmaceutical production to spot test of K2.2.2. No false-positive result of spot test for 
detection of K2.2.2 has been observed with the presence of seven different amines or other 
reagents commonly utilized in F-18 radiopharmaceutical synthesis. The interference test 
demonstrated  that the false-negative results are not due to the presence of amines or other 
chemical impurities. However, it was shown that the pH and the presence of ascorbic acid 
could lead to false-negative results. The specificity of iodoplatinate staining spot test for 
K2.2.2 detection has been investigated in this study. The detection of K2.2.2 is not 
interfered by other chemical impurities. However, the pH should be lower than 8.0, in order 
to make an accurate detection. The lower limit of the detection is 5 g/mL by this method, 
which is applicable for the test of K2.2.2 residue in F-18 FDG injection produced by routes 
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of synthesis that uses K2.2.2. Therefore, the iodoplatinate staining spot test is rapid and 
easy to operate, and sample saving (3 L versus 0.1 mL) for routine quality control. 
In chapter 3 and 4, I demonstrate that F-18 ML-10 PET/CT apoptosis imaging to be a 
potentially safe and effective clinical method for the assessment of early response of 
radiotherapy by pilot clinical studies. In F-18 ML-10 PET/CT apoptosis imaging, the tracer 
uptake in normal brain tissue is lower than that in tumor tissue, thus the anatomic 
positioning of tumor tissue and surrounding edema area could be accurately identified and 
visualized. More importantly, F-18 ML-10 PET/CT apoptosis imaging can be used for 
early prediction of the effectiveness of CK radiotherapy. A significant correlation between 
the rate of change in F-18 ML-10 uptake in the tumor and the rate of subsequent change in 
tumor volume was observed. In comparison to the therapeutic response in different cancer 
types, a rapid response in radioactivity, as well as subsequent tumor volume change, has 
been observed in malignant tumors, which tends to be more sensitive to CK treatment. 
Besides, the assessment to malignant tumor shows a more linear relationship with the 
volume change. Another comparison indicates that the therapeutic response of CK 
treatment is not significantly correlated with the apoptosis level before CK treatment by 
the study. By evaluation on applicability of this method to different patients, the F-18 ML-
10 gives a better assessment to patients aged >50. In chapter 3, the early assessment of 
therapeutic response by the F-18 ML-10 apoptosis imaging has been first applied to lung 
cancer, and the result of this assessment is consistent with that of traditional evaluation. 
Moreover, this study provides evidence that CK treatment could be harmful to heart tissue, 
due to a rapid apoptotic response from heart tissue after radiotherapy. A follow-up animal 
study suggests that 20 Gy radiation could induce a rapid apoptosis response of heart tissue 
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in the radiotherapy. Therefore, it is indicated that this method could be potentially used for 
the assessment of subsidiary-injury of lung cancer radiotherapy. However, as a pilot study, 
the amount of clinical cases is limited. Therefore, more future studies need to be carried 
out to further evaluation of the safety and efficacy of this method. 
In chapter 5, I demonstrate the sensitivity investigation of novel molecular probes for 
real-time guidance for tumor removal surgery. The limit of measurement of SERS particles 
is 10 thousand times lower than QD800, even 20 thousand times lower than IR800. 
Furthermore, the dynamic range of SERS nanoparticles is more than 300-fold higher than 
other 2 imaging probes. These parameters are important for the application of SpectroPen. 
The Limits of Detection, on one hand, determines the minimal quantity of the injection of 
contrast agents, which could help with reducing side effect and toxicity. On the other hand, 
weak tumor-margin signals that are 50-60-fold lower than the central tumor signals. The 
wider dynamic range provides opportunity for simultaneous measurement without 
adjusting the data acquisition parameters. I also have demonstrated the classification of 
tumor tissue from inflammatory tissues by a quad-modality molecular imaging system with 
application of three different molecular probes in an animal model. F-18 FDG traces the 
abnormal metabolic activities by PET imaging. However, the tumor site and inflammation 
tissue both have high metabolism, thus could not be distinguished by PET in this disease 
model. T-99m 3PRGD2 reveals the neovascularization of the cancer cells by SPECT 
imaging, and Cy7-entrapped CCPM nanoparticles preferentially accumulate in tumor site 
because of the EPR effect. From either the PET image or SPECT image alone, the tumor 
area remained unclear. With the comprehensive information collected from four modalities, 
the tumor tissue has been successfully distinguished from other false-positive signal from 
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inflammation. Therefore, it is suggested that the tumor tissue could be distinguished in vivo 
by appropriate application of multimodality molecular imaging along with multiple 
molecular probes. In current stage, many molecular probes are only available for 
preclinical uses, which may limit the clinical application of multimodality imaging. With 
the development of more safe and efficacious molecular probes, the molecular imaging 
will be a powerful weapon for the classification and distinguish of tumor for early diagnosis. 
In sum, this dissertation demonstrates following creative research: 
1. The interference in K2.2.2 detection K2.2.2 detection in quality control in the 
synthesis of F-18 radiopharmaceuticals has been demonstrated. 
2. Application and evaluation on F-18 ML-10 assessment of therapeutic response has 
been conducted and discussed, by pilot clinical study on 29 cases of patient with 
intracranial tumor. 
3. First application on lung cancer therapeutic response assessment by F-18 ML-10 
PET imaging has been conducted and the potential future application has been discussed. 
4. The sensitivity of three widely used optical probes for SpectroPen detection has 
been investigated, and an application on a quad-modal molecular imaging system has been 
conducted. 
As for limitations and future research aims, the clinical investigation on F-18 ML-10 
was limited by the amount of clinical cases. Therefore, more clinical studies need to be 
carried out to further evaluation of the safety and efficacy of this method.
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APPENDIX A. A PRELIMINARY STUDY OF F-18 FALLYPREIDE 
PET/CT BRAIN IMAGING 
 As a preliminary study of brain imaging of PET/CT, we investigated the 
visualization of dopamine D2/D3 receptors by F-18 fallypride in normal volunteers by 
using AMIC Ray-Scan 64 PET/CT. This work was done during July 2014 – May 2015. 
The dysfunction of dopamine system, a neurotransmission mode playing important roles 
in human brain, is implicated in many disorders in nervous system, such as Parkinson’s 
disease (PD), Attention Deficit Hyperactivity Disorder (ADHD). F-18-fallypride is a 
radioactive molecular probe for Positron Emission Tomography (PET) visualizing the 
Dopamine D2/D3 receptors in striatal and extrastriatal areas.[180-182]  
15 normal volunteers (8 males and 7 females) were investigated with AMIC Ray-Scan 
64 PET/CT. The F-18-fallypride was injected intravenously (2.96MBq/kg) to normal 
volunteer 1 hour prior to PET/CT brain scanning. Image reconstruction and data analysis 
was performed by using AMIC Ray-Scan 64 PET/CT software. 
Reconstructed by AMIC Ray-Scan 64 PET/CT software, the image of dopamine 
system in extrastriatal areas including substantia nigra and red nucleus is visualized clearly, 
and signal distribution of F-18 fallypride in caudate nucleus and putamen in left and right 
side is homogeneous and symmetrical in normal volunteers’ brain scanning (result is 
depicted in Figure A1). 
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Figure A1 – Signal distribution of F-18 fallypride in caudate nucleus and putamen in 
left and right side is homogeneous and symmetrical. Adapted from Zhou, et al [183]. 
F-18 fallypride PET/CT scanning is a promising method in visualizing of 
neurotransmitters like dopamine receptors due to the decay rate and its strong signal, 
comparing to other radiotracers. In this study, we confirmed that the AMIC Ray-Scan 64 
PET/CT system, as well as F-18 fallypride, performs excellently in dopamine D2/D3 
receptors imaging in normal volunteers. Thus, this Ray-Scan system could be widely used 
in drug discovery and other clinical applications. 
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